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Abstract 
 
Guruprasad R. Pattar 
 
 
A NUTRIENT NETWORK REGULATING CELLULAR CHOLESTEROL and 
GLUCOSE METABOLISM 
 
 Insulin resistance, a hallmark of type 2 diabetes (T2D), is associated with 
accompanying derangements such as hyperinsulinemia that promote the 
progression of insulin resistance, yet a mechanism(s) is imperfectly understood. 
Data have demonstrated that hyperinsulinemia promotes insulin resistance as 
evidenced by diminished ability of insulin to mobilize glucose transporter GLUT4 
to the plasma membrane (PM). We found that loss of PM phosphatidylinositol 
4,5-bisphosphate (PIP2)-regulated filamentous actin (F-actin) structure 
contributes to hyperinsulinemia-induced insulin resistance. We tested if 
increased glucose flux through hexosamine biosynthesis pathway (HBP) causes 
dysregulation of PM components necessary for GLUT4 translocation. Increased 
HBP activity was detected in 3T3-L1 adipocytes cultured in hyperinsulinemia (5 
nM Ins; 12 h) and also 2 mM glucosamine (GlcN), a distal HBP activator, 
inducing losses of PM PIP2 and F-actin. In accordance with HBP flux directly 
weakening PIP2/F-actin structure, inhibition of the rate-limiting HBP enzyme 
(glutamine:fructose-6-phosphate amidotransferase) restored F-actin and insulin 
responsiveness. Furthermore, less invasive challenges with glucose led to 
vii 
PIP2/F-actin dysregulation. New findings support a negative correlation between 
PM cholesterol accrual, PIP2/F-actin structure and GLUT4 regulation. These data 
stemmed from parallel study aimed at understanding the antidiabetic mechanism 
of the nutrient chromium (Cr3+). We found that chromium picolinate (CrPic) 
enhanced insulin-stimulated GLUT4 trafficking via reduction in PM cholesterol. In 
line with glucose/cholesterol toxicity findings, we demonstrated that therapeutic 
effects of CrPic occurred solely in adipocytes with increased HBP activity and a 
concomitant elevation in PM cholesterol. Mechanistically, data are consistent 
with a role of AMP-activated protein kinase (AMPK) in CrPic action. These data 
show that CrPic increases AMPK activity and perhaps suppresses cholesterol 
synthesis via distal phosphorylation and inactivation of 3-hydroxy-3-
methylglutaryl CoA reductase (HMGR), a rate-limiting enzyme in cholesterol 
synthesis. Continued study of the consequence of increased HBP activity 
revealed alterations in cholesterogenic transcription factors – Sp1, SREBP-1, 
and NFY – with Sp1 showing a significant increase in O-linked glycosylation. 
Consistent with Sp1 modification eliciting maximal transcriptional activation of 
SREBP-1, Hmgr mRNA was significantly enhanced. In conclusion, these data 
are consistent with a central role of PM cholesterol in glucose transport and 
suggest perturbations in this lipid have a contributory role in developing insulin 
resistance. 
      
                                                                  Jeffrey S. Elmendorf, Ph.D., Chair 
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Chapter I 
 
Introduction 
 
 Diabetes is currently reaching epidemic proportions worldwide. Incidence 
of this disease is growing at a staggering rate. It is now appreciated that there 
are multiple avenues and chronic metabolic insults involved in the development 
of type 2 diabetes (T2D) including the hallmark characteristic, insulin resistance. 
Insulin resistance is a state whereby peripheral tissues (adipose, skeletal muscle, 
and liver) become unresponsive to the actions of insulin. This resistance occurs 
at the cellular level and is associated with diminished glucose transport in 
skeletal muscle and adipose tissue. Ironically, compensatory hyperinsulinemia is 
considered a key derangement that promotes the progression and worsening of 
insulin resistance, yet a mechanism(s) is imperfectly understood. Elucidating how 
insulin resistance develops and eventually results in T2D remains a fundamental 
challenge in biology and a significant issue in medicine. Now, pharmacologic 
therapies are primarily designed to minimize accompanying defects associated 
with conditions of T2D and only a few medications present are designed to slow 
the progression of insulin resistance. None of these therapies have been proven 
to reverse the critical factor of glucose intolerance in these patients without 
significant surgical or lifestyle intervention. However, it can be speculated that 
early therapeutic intervention, during the pre-diabetic state, may essentially 
reverse this defect and protect an individual from the development of T2D. 
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Nutritional supplementation, especially that of chromium (Cr3+), is thought to 
perhaps alleviate glucose intolerance yet the mechanism is unclear. 
 
 Recent evidence from our laboratory as well as others have appreciated 
that cellular disturbances found at the level of the plasma membrane (PM) is a 
key contributing factor to diminished glucose transport in both fat and muscle 
cells by conditions of the diabetic milieu [1]. Namely, PM cholesterol and its role 
in determining membrane fluidity is an important mediator of glucose transport in 
these cells. In addition, modifications in PM cholesterol levels concomitantly 
occur alongside changes in PM phosphatidylinositol-4,5-bisphosphate (PIP2) 
amount and cortical F-actin (F-actin) structure that regulate glucose transporter 4 
(GLUT4) translocation necessary for cellular glucose uptake.  
 
 This introduction reviews evidence about what is currently known about 
the fundamentals of insulin action. Specifically, evidence will be presented 
regarding the role of PM cholesterol in regulating glucose transport. A brief 
overview of insulin-regulated glucose transport will be highlighted before outlining 
the cellular components necessary for insulin responsiveness and these cellular 
defects contributing to insulin resistance. Next, several sections are devoted to 
presenting research on mechanisms of PM cholesterol regulation of insulin-
stimulated glucose transport. Within the same context, mechanisms involved in 
the regulation of cellular cholesterol homeostasis are also outlined. Finally, 
recent data highlighting the benefits of Cr3+ supplementation will be detailed.  
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1. Insulin-mediated glucose regulation 
 Insulin action is important in regulating many metabolic processes in the 
body. Insulin is a hormone that is produced and stored in the β-cells of the 
pancreas. In the post-prandial state, elevated plasma glucose levels stimulate 
secretion of insulin from the pancreas into the blood. The circulation of insulin 
allows for it to bind peripheral tissues that are important in regulating whole body 
glucose homeostasis, namely adipose tissue, skeletal muscle, and the liver. The 
cellular action of insulin, which will be detailed below, stimulates the uptake of 
glucose into adipocytes and skeletal muscle myotubes, allowing for critical 
cellular processes of energy regulation to occur. In the liver, insulin’s main 
responsibility is to inhibit hepatic glucose production or gluconeogenesis thus 
representing a shift from the fasted state to the fed state in the body. This 
intricate balance of glucose by insulin accounts for maintenance of plasma 
glucose concentrations in healthy individuals within very strict limitations, 
generally not falling below 70 mg/dL or straying upwards from 99 mg/dL. The 
action of insulin at the level of the whole body actually begins at cell membranes 
where the insulin receptor (IR) is localized. The focus of this thesis was GLUT4 
regulation by insulin in skeletal muscle and fat.  
 
2. Cellular Insulin Action/Glucose Transport 
 On a cellular level, insulin is able to regulate changes in plasma glucose 
concentrations via the regulation of subcellular trafficking of GLUT4 in adipose 
tissue and skeletal muscle. This process is the main mediator of glucose 
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disposal, which accounts for greater than 80% of post-prandial glucose disposal. 
In the basal state, GLUT4 cycles continuously between the PM and intracellular 
membranes, with the majority of transporters being bound and residing 
intracellularly [2-5]. Insulin stimulation causes a large increase in the rate of 
exocytosis of GLUT4 vesicles and a relatively smaller decrease in the rate of 
endocytic internalization resulting in a net increase of GLUT4 present at the PM 
allowing for cellular glucose transport [6-8]. In a simplistic fashion, this seems like 
a straightforward process. However, research has shown that the regulation of 
GLUT4 trafficking by insulin is well-regulated and incredibly complex and that 
defects in GLUT4 translocation contribute to insulin resistance.  
 
 In addition, insulin plays a substantial role in the regulation of glucose 
homeostasis within the liver. As will be detailed below, insulin action of 
hepatocytes involves ‘classic’ proteins involved in insulin signal transduction. In 
hepatocytes, the main purpose of insulin is to inhibit and suppress glucose 
production or gluconeogenesis. Two components that play an important role in 
regulating gluconeogenesis in the liver include the forkhead transcription factor, 
FOXO1, and peroxisome proliferative activated receptor-γ co-activator 1 (PGC-
1α) which is another transcriptional co-activator necessary for inducing 
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G-6-Pase). FOXO1 is a transcription factor that can bind 
directly to the promoters of these gluconeogenic genes thus causing enzymatic 
increases in regulators of glucose production in the ‘starved’ state in the absence 
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of insulin. Insulin signaling in hepatocytes results in phosphorylation of FOXO1 
and subsequently disrupts its ability to localize to the nucleus thus silencing the 
transcription of gluconeogenic enzymes [9]. The aforementioned transcriptional 
coactivator, PGC-1α, is also under the regulation of insulin. PGC-1α is able to 
bind FOXO1 and enhance its transcriptional activity [9]. Insulin is able to disrupt 
the interaction between FOXO1 and PGC-1α thus inhibiting the production of 
gluconeogenic enzymes. In addition to PGC-1α, insulin may also target other 
coactivators of transcriptional activity of the p300/CREBP family. Evidence has 
suggested that phosphorylation of p300 by the insulin signaling cascade shuts 
down transcription of PEPCK and G-6-Pase [10]. This effect of insulin on 
inhibiting gluconeogenic processes is important in regulating glucose 
concentrations in the blood because perturbations in insulin sensitivity can be 
associated with unregulated hepatic glucose production. The uptake of glucose 
into adipocytes and myotubes, as well as the inhibition of glucose production in 
hepatocytes, requires an extensive signal transduction cascade that is still 
incompletely understood. 
 
2.1. Insulin Signal Transduction  
 The mechanism by which insulin action can influence GLUT4 translocation 
or inhibition of gluconeogenesis requires an extensive, and still somewhat 
incomplete, network of signaling molecules which will be detailed here. The 
beginning of the insulin signal and its translation to cellular processes begins at 
the level of the PM. After this peptide hormone’s journey through the 
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bloodstream, it is able to bind to the insulin receptor (IR), which is localized at the 
PM. The IR is composed of two disulphide-linked heterodimers, each of which 
has an α and β subunit. The action of insulin binding to its receptor induces a 
conformational change in the receptor allowing for stimulation of intrinsic tyrosine 
kinase activity and autophosphorylation of its β-subunit on specific tyrosine 
residues [11, 12]. This stimulatory activity of tyrosine phosphorylation by the β 
subunits can lead to downstream signal transduction, including phosphorylation 
of a host of proteins. In particular, proteins that are phosphorylated by the IR 
include all the members of the insulin receptor substrate family (IRS-1, -2, -3, -4, 
-5, and -6), Gab-1, Shc, p62dok, signal regulatory protein (SIRP) family members, 
APS (adapter protein containing a pleckstrin homology and Src-homology 2 
domain). 
 
 Insulin receptor substrates (IRS) are docking proteins that associate with 
the IR in order to regulate its signal by differentiating the insulin signal into its 
various metabolic and gene regulatory functions. Of the six IRS proteins 
identified, only the specific isoforms IRS-1 and IRS-2 have been firmly placed as 
a mediator of glucose homeostasis. Animal models have been useful in 
determining the importance of IRS molecules. In genetically-manipulated mouse 
models, the knockout of IRS-1 has been demonstrated to be associated with 
severe growth retardation and mild peripheral insulin resistance [13, 14]. 
Conversely, ablation of IRS-2 in knockout mice develop frank diabetes 
simulataneous with impaired growth of pancreatic β-cells, β-cell failure, and 
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insulin resistance at the liver [15]. Cell culture studies utilizing L6 myotubes 
displayed that siRNA knockdown of IRS-1 significantly diminished insulin-
stimulated GLUT4 translocation and glucose uptake whereas IRS-2 knockdown 
in these same cells resulted in no diminishment of glucose transport [16]. Taken 
together, these studies suggest that both molecules are important in the action of 
insulin where IRS-1 is critical in peripheral adipose and skeletal muscle insulin 
action while IRS-2 seems to be important in the liver and β-cell sensitivity. 
Additionally, compensatory mechanisms occur due to molecular redundancy 
found in this family of proteins. For example, in IRS-1 knockout mice, IRS-3 was 
identified as the principal mediator of insulin signaling and became the key 
substrate of IR tyrosine phosphorylation events. However, studies performed in 
humans displayed a lack of functional IRS-3 protein or gene in adipose tissue 
[11]. In regards to IRS-4, -5, and -6 family members, they seem to play a minor 
role in glucose homeostasis. IRS-4 knockout studies have demonstrated mild 
defects in growth and glucose homeostasis, along with reproductive 
abnormalities. However, the actual importance of IRS-4 on normal insulin action 
is debatable since skeletal muscle (the insulin-sensitive tissue responsible for 
~80% of whole body glucose uptake) has not been shown to express IRS-4 [17]. 
Conversely, IRS-5 and IRS-6 are substrates that may be phosphorylated by 
insulin; however, they do not activate the downstream signaling component 
phosphatidylinositol 3-kinase (PI3K) [17]. Therefore, the roles of IRS-1 and -2 as 
mediators of the metabolic effects of insulin action are fairly well established 
whereas the role of these newly discovered members on insulin action is still 
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somewhat speculative. Regardless, IRS proteins are key intermediates in 
propagating the insulin signal from outside the cell to the inside resulting in key 
cellular metabolic actions. 
 
 After rapid insulin-induced tyrosine phosphorylation of IRS-1 and/or IRS-2, 
docking sites are now created allowing for the recruitment of signaling molecules 
with Src homology 2 (SH2) domains, which includes Class IA PI3K [18]. PI3K is a 
heterodimer, made up of the SH2-containing regulatory subunit, p85, and also 
the p110 catalytic subunit. The binding of the p85 regulatory subunit to IRS 
proteins is able to both activate the catalytic subunit p110 while also localizing 
the kinase near the PM. This PM localization of PI3K places the enzyme near its 
substrate phosphatidylinositol 4,5-bisphosphate (PIP2) allowing for the 
phosphorylation of this PM lipid on the 3 position of the inostiol ring, forming 
phosphatidylinositiol 3,4,5-trisphosphate (PIP3). The formation of PIP3 is 
necessary for the translocation of two pleckstrin homology (PH) domain-
containing proteins, Akt (protein kinase B, PKB) and phosphoinositide-
dependent-kinase-1 (PDK1) which can further propagate the insulin signal to 
stimulate GLUT4 translocation.  
 
 Upon membrane recruitment, the 60 kDa serine/threonine kinase Akt can 
be phosphorylated at two key sites, serine 473 (Ser473) occurring first by PDK2 
[19] and threonine 308 (Thr308) which occurs after Ser473 phosphorylation that 
stabilizes interaction with PDK1 [20, 21]. Currently, there are three identified Akt 
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isoforms. In Akt1-deficient mice, there was no diminished effect of glucose 
homeostasis observed, although their growth was severly compromised [22]. 
However the deleted isoform, Akt2, in mice caused a reduction in insulin 
sensitivity [23]. This then allowed for the identification that Akt2 was the 
predominant isoform found in insulin-sensitive tissues, adipose and skeletal 
muscle suggesting that this isoform is necessary for normal glucose 
homeostasis. In cell culture studies utilizing siRNA gene silencing of Akt1 and 
Akt2 revealed that Akt2 plays a predominant role in the translocation of GLUT4 
upon insulin stimulation [24, 25] whereas Akt1 is only a minor contributor. 
Intracellular localization analyses lend further credence to Akt2 as the primary 
mediator of insulin-stimulated GLUT4 translocation. Utilizing cultured adipocytes, 
it was demonstrated that Akt1 was found primarily in cytosolic fractions whereas 
Akt2 can be found in both cytosolic and membrane fractions. Using 3T3-L1 
adipocytes, it was discovered that Akt2 was associated with GLUT4-containing 
vesicles and that insulin increases Akt2-GLUT4 association while concomitantly 
phosphorylating various GSV component proteins [26, 27]. The role of Akt3 in 
physiology is currently unknown. Although Akt is an important signaling mediator, 
a distal component of the insulin signaling cascade involved in GLUT4 
translocation has been recently identified.  
 
 The importance of Akt on glucose transport was enhanced by the 
discovery of Akt substrate of 160 kDa (AS160) which provided a downstream 
signaling effector between IR and GLUT4 transolcation [28]. Interestingly, AS160 
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was originally named TBC1D4 before its function was known [29]. A close 
relative of this protein is TBC1D1, a protein that contains similarities yet 
interesting differences to AS160/TBC1D4. While both of these proteins are 
phosphorylated on Ser/Thr residues similarly, TBC1D1 exhibits Thr596 and 
Ser507 phosphorylation sites whereas AS160 demonstrates Thr642 and Ser570 
phosphorylation sites [29]. AS160 contains a GTPase-activating (GAP) domain 
for Rab proteins or small G proteins involved in the trafficking of vesicles. This 
was demonstrated in a study of 3T3-L1 adipocytes that contain mutated 
phosphorylation sites on AS160 which then markedly inhibited insulin-stimulated 
GLUT4 transolcation [30]. Since that time, knockdown studies of AS160 have 
demonstrated increased basal PM GLUT4 due to increased exocytosis in 3T3-L1 
adipocytes. This can then be rescued via transfection of wild-type human AS160. 
However, when the GAP domain is mutated in these transfected human AS160 
proteins, no rescue of this increase in basal GLUT4 is experienced. This 
suggests that in basal condition, AS160 is unphosphorylated and associated with 
GLUT4 vesicles with its intrinsic GAP activity consistently inactivating Rab 
proteins, due to it being bound to GDP. Conversely, when stimulated with insulin, 
AS160 can then be phosphorylated causing an inhibitory effect on GAP activity, 
allowing for Rab proteins to be bound to GTP and thus active for proper GLUT4 
translocation. [31-33]. As mentioned, substrates of AS160 are Rab proteins. 
Specific isoforms of Rab proteins that are heavily associated with AS160 and 
GLUT4 containing vesicles are Rabs 2A, 8A, 10, and 14 [31, 34, 35]. Since then, 
Sano et al. has demonstrated through knockdown studies that Rab10 is the main 
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participant in GLUT4 translocation in 3T3-L1 adipocytes [36]. In skeletal muscle 
and cultured myotube anaylses, the specific Rab protein(s) associated with 
GLUT4 translocation are still unknown [29].  
 
 In addition to the activation of Akt, PIP3 along with PDK1 have been 
demonstrated to activate atypical protein kinase C (aPKC, PKC ζ/λ). Both of 
these isoforms have regulatory roles in glucose transport [37]. Overexpresion of 
PKCζ stably increased glucose uptake in fibroblasts, adipocytes, and L6 
myotubes. Whereas, a dominant-negative form of this protein exhibited 
decreased glucose transport basally and upon insulin stimulation [37]. In 
accordance, data now exist that expression of a constitutively active aPKC 
mimics insulin’s action on GLUT4 translocation and glucose transport.  Despite 
the importance of propagation of the insulin signal, evidence for insulin signaling-
independent translocation of GLUT4 has now been offered. Importantly, there is 
evidence from our laboratory and others that demonstrate cellular dynamics 
associated with PM lipids and its effects on the underlying cortical filamentous 
actin (F-actin) play an important role in insulin-stimulated glucose transport. 
 
2.2 PM Lipid and Cytoskeletal Regulation of GLUT4 Translocation 
 It has recently been appreciated that cellular cytoskeletal rearrangements 
play an important role in GLUT4 translocation. Specifically, the role of cortical 
actin is essential in the translocation of GLUT4 [38-43]. Cellular cortical actin 
exists in two forms: monomeric globular actin (G-actin) and filamentous actin (F-
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actin). Polymerization of monomeric actin into filamentous actin requires ATP 
hydrolysis. Evidence exists that insulin promotes the formation of F-actin 
structure [44, 45] and that disruption of this structure, with such agents as 
latrunculin B or the actin depolymerizing agent cytochalasin D, causes an 
inhibition of insulin-stimulated GLUT4 translocation [38, 46, 47]. It should be 
noted that in these situations, the disruption of actin filaments by pharmacological 
means does not appear to induce changes in proximal insulin signaling, such as 
insulin’s ability to activate PI3K and Akt [43, 44, 48]. Intriguingly, utilizing 
jasplakinolide, an F-actin stabilizing compound, an inhibition of GLUT4 
translocation is witnessed, suggesting that a dynamic reorganization of actin is 
required for the insulin to be effective [43]. Interestingly, regulation of this cortical 
actin structure occurs via actin-binding proteins and membrane lipids. Previous 
data from our laboratory have explored the regulatory nature of a particular PM 
phosphoinositide on cortical F-actin structure. The coordination of 
rearrangements of the actin cytoskeleton is thought to occur through signals 
transmitted by this membrane phosphoinositide, PI 4,5-P2 (PIP2). PIP2 is 
generated from phosphorylation of PIP by PI4P 5-kinase and is present in 
relative abundance at the PM, representing around 1% of all PM phospholipids 
[49]. Multiple studies have shown that the sequestration or hydrolysis of PI 4,5-P2 
downregulates the interaction between the PM and underlying cytoskeletal 
structures, resulting in a depletion of cortical F-actin [50-54]. As mentioned, this 
role of PM PIP2 is critical in optimizing the reorganization of cortical F-actin 
structure necessary for GLUT4 translocation. Furthermore, our laboratory has 
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identified another important membrane component that interacts with PM PIP2/F-
actin regulation of GLUT4 translocation. An essential lipid in the context of 
membrane integrity, the role of PM cholesterol has been established in 
modulating membrane dynamics. In the context of GLUT4 translocation, we have 
shown that manipulations in PM cholesterol amount are sufficient in altering the 
cell’s ability to regulate glucose transport.  
 
 Work from our laboratory and others has illustrated the potential role of 
membrane cholesterol content in the regulation of GLUT4 mobilization to the PM. 
It is generally well accepted that PM cholesterol is an important determinant of 
membrane fluidity as relative increases in cholesterol causes a highly ordered, 
gel-like state. Kanzaki et al. utilized PIP5K overexpression to generate elevated 
levels of PIP2 in 3T3-L1 fibroblasts and adipocytes. These authors demonstrated 
that cholesterol loading of fibroblasts expressing PIP5K increased formation of 
membrane vacuoles coated with F-actin, cortactin, dynamin, and the actin 
regulatory protein N-WASP, which inhibited the endocytosis of GLUT4. This led 
the authors to hypothesize that cholesterol has an effect on trafficking events 
such as GLUT4 endocytosis by altering membrane thickness and curvature or 
through its influence on PIP2 level and distribution [55]. Nonetheless, it is 
apparent that there is a delicate balance of PM cholesterol amount for optimal 
GLUT4 translocation. This idea was evident in studies from our group exhibiting 
that lowering of PM cholesterol by sphingomyelinase- an enzyme that degrades 
the cholesterol-associated phospholipid sphingomyelin- stimulated GLUT4 
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translocation [56]. Additional use of a moderate concentration of methyl-β-
cyclodextrin (βCD) (2.5 mM) that was demonstrated to remove 44% of PM 
cholesterol resulted in an increase in GLUT4 translocation independent of 
enhancing any insulin signaling properties. We have also witnessed similar 
results utilizing other cholesterol lowering agents, such as nystatin and filipin [56]. 
New evidence from our laboratory has documented that the essential nutrient, 
chromium (Cr), has the ability to enhance insulin action on 3T3-L1 adipocytes 
through PM cholesterol reduction. As will be discussed later and is the focus of 
these studies, the balance of PM cholesterol is an important determinant in the 
influence of cellular glucose transport. We have found that key components of 
the diabetic milieu, including hyperinsulinemia, hyperlipidemia, and 
hyperglycemia, are all associated with increases in PM cholesterol and a 
concomitant dysregulation of the underlying cortical F-actin structure. Lending 
further evidence for the importance of PM cholesterol on GLUT4 translocation is 
the ability of insulin-sensitizing agents (i.e. CrPic and known AMPK activators) to 
enhance cellular insulin action and glucose transport along with PM cholesterol 
lowering events [57, 58].  
 
2.3 Hyperinsulinemia and Insulin Resistance 
 A continuous component of insulin resistance is hyperinsulinemia [59, 60]. 
This compensatory increase in insulin during the insulin-resistant state initially 
offsets the reduced ability of insulin to stimulate GLUT4 translocation and 
glucose uptake, which is essential for the maintenance of blood glucose 
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homeostasis. However, in vivo and in vitro studies demonstrate that the 
hyperinsulinemic state has a negative effect on insulin action. The temporal 
sequence in the pathogenesis of type 2 diabetes resulting in compensatory 
elevations of blood insulin and blood glucose is unknown and is the topic of a 
review by the late J Dennis McGarry [61]. In this review, the possibility that 
hyperinsulinemia and insulin resistance may arise simultaneously or by a 
preexisting defect in leptin signaling is raised. A possibility in the temporal 
sequence of the development of insulin resistance that McGarry favored is that 
hyperinsulinemia may beget insulin resistance, possibly as a necessary 
adaptation to prevent hypoglycemia. The breakdown of glucose homeostasis is 
actually secondary to disturbances in lipid breakdown. Interestingly, the cause of 
hyperinsulinemia may be in response to dyslipidemic conditions present in the 
blood whereby plasma free fatty acid concentrations are significantly increased. 
This elevation in fatty acids may inhibit glucose transport in skeletal muscle 
rendering a state of insulin resistance. However, an intriguing possibility raised 
by McGarry is that the elevation of fatty acids, in itself, may provide a stimulus for 
insulin secretion, leading to hyperinsulinemic conditions.  
 
 Plasma insulin concentrations have been measured in multiple population-
based studies. For example, as reviewed by Ferrannini [62] in the San Antonio 
Heart Study, a survey involving ~3,000 subjects stratified by age and 
socioeconomic condition, fasting insulin typically ranged between 1 and 50 µU/ml 
(6 and 300 pM), while 2 h post-glucose plasma insulin concentrations ranged 
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between 1 and 700 µU/ml (6 and 4,200 pM). Hyperinsulinemia was defined as a 
value 2 standard deviations above the mean (or the top 2.5%) of the healthy 
(non-obese, non-diabetic) group, the low end value being 31 µU/ml (186 pM). In 
the population screened, 8% had fasting insulin values exceeding this level. 
Clearly, the prevalence of hyperinsulinemia may vary in different populations 
depending on environmental and genetic factors. Nevertheless, in the San 
Antonio Heart Study, the clinical impact of hyperinsulinemia was large. Obesity, 
impaired glucose tolerance, T2D, hypertension, and hypertriglyceridemia were 
found to be two to three times more prevalent in the 239 individuals with fasting 
insulin levels greater than 31 µU/ml (186 pM) than in the 2,700 subjects with 
fasting insulin concentrations below that level. This quantitative definition of 
hyperinsulinemia is useful to the extent that a clinically relevant endpoint is 
identified. Cell culture studies have attempted to decipher a mechanism by which 
hyperinsulinemia may be contributing to this decrement of insulin sensitivity.  
 
 To date, extensive study has built a good understanding of how insulin 
itself can be involved in the staging of diabetes. For example, chronic exposure 
to pharmacological doses of insulin (≥100 nM) have been shown by several 
laboratories [63-65] to markedly attenuate expression levels and/or activity states 
of the IR, IRS-1, PI3K, At, and GLUT4 proteins in 3T3-L1 adipocytes and, thus, 
produce a defect in the ability of the cell to respond to subsequent acute insulin 
stimulation with an increase in GLUT4 translocation and glucose transport. On 
the other hand, similar defects in the ability of insulin to acutely regulate the 
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glucose transport system can be induced by physiological doses of insulin (≤ 5 
nM) that are not associated with disturbances in early insulin signaling [66, 67]. 
Therefore, defects positioned more distal in the insulin signaling pathway may 
contribute to the insulin-mediated cellular insulin resistance. Within this thesis, a 
study conducted by our laboratory provided evidence that sutained exposure of 
3T3-L1 adipocytes to a physiological dose of insulin results in a marked loss of 
cortical F-actin and PM PIP2. These studies will be presented in Chapter II 
supporting a new membrane/cytoskeletal model of insulin resistance. 
 
2.4 Hexosamine Biosynthesis Pathway Involvment in Glucose Intolerance 
 Marshall et al. [68], using primary adipocytes, first proposed that excess 
glucose flux through the heoxsamine biosynthesis pathway (HBP) may contribute 
to insulin resistance. In normal healthy conditions, HBP is a relatively minor 
pathway in the utilization of glucose representing only ~2-5% of total intracellular 
glucose [69]. Glucose entry into the HBP is catalyzed by the first and rate-limiting 
enzyme, glutamine:fructose-6-phosphate (F-6-P) amidotransferase (GFAT), 
which converts F-6-P and glutamine into glucosamine 6-phosphate (GlcN-6-P) 
and glutamate. GlcN-6-P is metabolized to UDP-N-acetylglucosamine (UDP-
GlcNAc), the major product of the pathway [68]. UDP-GlcNAc and other amino 
sugars generated by the pathway provide building blocks of glycosyl side chains 
for proteins and lipids. UDP-GlcNAc is also the obligatory substrate of O-linked 
N-acetylglucosamine (O-GlcNAc) transferase (OGT), a cytosolic and nuclear 
enzyme that modifies Ser/Thr residues of proteins by attaching single GlcNAc 
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moieties in O-linkage [70, 71]. O-GlcNAcylation frequently occurs on transcription 
factors and often involves known phosphorylation sites, suggesting a regulatory 
role for this post-translational modification [72]. Beginning in the 1950s, multiple 
in vitro and in vivo studies in rodent models have demonstrated that chronic 
elevated flux through the HBP may represent a possible mechanism by which 
changes in cellular glucose handling can lead to insulin resistance. GFAT levels 
are markedly elevated in skeletal muscle of diabetic patients [73]. In order to 
place the HBP as a central player in the development of insulin resistance, there 
are a few routine experimental procedures that have been utilized. The first is a 
chronic incubation of cells to a state of hyperglycemia, inevitably increasing 
intracellular glucose flux through this pathway. Second, treatments with 
glucosamine, a compound that directly enters the HBP distal to the rate-limiting 
enzyme GFAT, also subsequently increases cellular UDP-GlcNAc levels and 
thus O-linked glycosylation modifications of proteins. Finally, changes in 
expression and activity of GFAT have been undertaken to further analyze HBP 
activity on insulin resistance. Interestingly, incubation of adipocytes with a potent 
inhibitor of GFAT, 6-Diazo-5-Oxo-L-Norleucine (DON), was able to reverse this 
state of insulin resistance in adipocytes [68]. Modest overexpression 
(approximately 20%) of OGT in fat, skeletal and cardiac muscle of transgenic 
mice was sufficient to induce insulin resistance as assessed by diminished 
glucose disposal and hyperinsulinemia [74]. It was also noted in this study that 
the ob gene and its product, leptin, is influenced by hexosamines. Evidence from 
these OGT overexpressing mice displayed hyperleptinemia due to an observed 
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70% increase in leptin mRNA [75]. However, a direct relationship between 
elevated O-linked glycosylation and the development of insulin resistance is still 
imperfectly understood. However, GlcN-induced insulin resistance results in 
tremendous cellular accumulation of GlcN-6-PO4 whereas this compound is 
nearly undetectable in cells exposed to glucose alone. Importantly, GlcN-6-PO4 
accumulation depletes intracellular ATP which was clearly demonstrated by 
Hresko et al. in 3T3-L1 adipocytes incubated with high concentrations of GlcN, in 
the presence of insulin and no glucose. However, under milder conditions lacking 
insulin and/or addition of an energy source, ATP depletion due to GlcN treatment 
becomes trivial or tyrosine phosphorylation-based abnormalities do not occur, yet 
GlcN-induced insulin resistance still occurs. Additional evidence for O-linked 
glycosylation in mediating insulin resistance is offered by treating 3T3-L1 
adipocytes with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)-amino-N-
phenylcarbamate (PUGNAc), an inhibitor of O-GlcNAcase (OGA) protein. OGA is 
a protein that is able to dynamically remove glycosylation modifications from 
proteins. PUGNAc inhibition of OGA has been demonstrated to cause a 
substantial increase in O-GlcNAc levels and the eventual development of insulin 
resistance [76]. Utilizing these experimental manipulations of proteins present in 
the HBP, an association between the development of insulin resistance and 
increased HBP activity is quite strong. Research from our laboratory has 
suggested a role of HBP in induction of defective glucose transport into 3T3-L1 
adipocytes. Additional data in rat epitrochlearis muscle incubated with PUGNAc 
for 19 h was sufficient in the induction of insulin resistance as assessed by 
 20 
diminished insulin-stimulated glucose uptake [77]. In this same study, no change 
was seen in the activity of insulin signaling molecules, including phosphorylation 
of AS160. The authors concluded in this study that PUGNAc was an effective 
inhibitor of O-GlcNAcase significantly increasing O-linked glycosylation on 
cellular proteins that then diminished skeletal muscle insulin sensitivity 
independent of attenuated insulin signaling effects [77]. As mentioned earlier, 
previous work from our group has suggested a new molecular framework for 
insulin-induced insulin resistance involving defects in PM PIP2-regulated cortical 
F-actin [1, 41]. One key focus of my thesis work was to determine whether a 
connection between these hyperinsulinemia-induced PM disturbances and 
increased HBP activity played a contributory role in insulin resistance. Since it 
has been previously shown that basal transcription factors involved in multiple 
cellular processes are frequently the target of O-linked glycosylation 
modifications [78], the findings outlined in Chapter II supported future study to 
determine whether the basis of PM cholesterol accrual in response to 
hyperinsulinemia is mediated via changes in key cholesterol regulatory 
transcription factors such as the sterol regulatory element-binding protein 
(SREBP).  
 
3. Cellular Cholesterol Homeostasis 
 Sterol regulatory element-binding protein (SREBP), a transcription factor 
that activates genes involved in fatty acid and cholesterol biosynthesis, maintains 
tight control of cellular cholesterol as first identified by the works of Brown and 
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Goldstein [79]. The SREBP family consists of three members, SREBP-1a, 
SREBP-1c, and SREBP-2 proteins. SREBP-1a and SREBP-2 are constitutively 
expressed in most tissues. These factors reside in an immature, 125 kDa form, 
localized to the ER/Golgi with SREBP cleavage-activating protein (SCAP). In 
addition, the insulin-inducible genes (Insig) interact with SCAP and 3-hydroxy-3-
methylglutaryl coenzyme-A (HMG-CoA) reductase (HMGR), the rate-limiting 
enzyme of cholesterol biosynthesis, in a manner dependent on levels of sterols. 
When intracellular sterol levels are high, sterols then bind SCAP and HMGR 
changing their conformation to favorably associate with Insig. Insig proteins are 
then able to either retain the SCAP/SREBP complex in the ER and also 
downregulate the levels of HMGR by promoting its ubiquitation and degradation. 
Conversely when intracellular sterol levels are low and cholesterol synthesis 
needs to be induced, this results in the 125 kDa form of SREBP being cleaved 
into a mature 68 kDa form that then can redistribute to the nucleus where it 
upregulates the transcription resulting in increased expression of proteins 
regulating cholesterol synthesis [80]. Additionally, intracellular cholesterol 
transport is essential for the maintenance of cholesterol homeostasis. The 
fundamental pathways in cholesterol metabolism (synthesis, uptake, gene 
regulation) all rely on its proper intracellular distribution among membranes and 
subcellular organelles [81]. 
 
 As mentioned above, our laboratory has extensive research interests in 
understanding cellular cholesterol homeostasis and how components of the 
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metabolic syndrome, including dyslipidemia, hyperinsulinemia, and even 
hyperglycemia, perturb this finely-tuned system. Work performed by Nadeau et 
al. demonstrated the ability of insulin to alter lipid content through alterations on 
SREBP-1 protein expression in both 3T3-L1 adipocytes and L6 myotubes. 
Incubating either 3T3-L1 adipocytes or L6 myotubes with physiological doses of 
insulin, 1-10 nM, for 24 hours was sufficient to enhance SREBP-1 protein 
expression [82]. Total cellular protein levels of SREBP-1 were increased under 
these conditions and inhibitors of downstream insulin signaling molecules could 
subsequently inhibit this. Specifically, it was demonstrated that the insulin-
induced upregulation of SREBP-1 in adipocytes could be blocked by various 
PI3K inhibitors, wortmannin (WT) and LY294002. Interestingly, the MAPK 
inhibitor, PD98059 (PD), was only effective in blocking insulin’s ability to induce 
SREBP-1 upregulation in L6 myotubes. Unlike in the adipocyte model, the 
aforementioned PI3K inhibitors did not display any effect in diminishing the role 
of insulin on SREBP-1 transcription. This suggests that insulin has dual 
functions, potentially occurring through different signaling mechanisms, that differ 
in L6 myotubes and 3T3-L1 adipocytes [82]. In light of this work, our laboratory 
has demonstrated that incubation of adipocytes or L6 myotubes with a 
physiological (5 nM) dose of insulin did not cause a significant defect in insulin 
signal propagation compared to control; however, significant decreases in 
glucose transport were observed along with increases in lipogenic mechanisms 
as demonstrated through PM cholesterol accrual [1, 41]. Studies demonstrating 
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the exact mechanism by which hyperinsulinemic conditions may induce cellular 
lipogenesis and PM cholesterol accrual are currently being undertaken.  
 
3.1 Role of HBP Flux & Transcription of Cholesterogenic Enzymes 
 Our data has identified the HBP as a mediator of diminished glucose 
transport thereby playing a role in the development of insulin resistance. The 
HBP has also been shown to mediate the glycosylation of an important 
transcription factor involved in regulating cholesterol synthesis, Sp1. This basal 
transcription factor with effects on many different cellular properties was first 
identified to be glycosylated by Han et al. [83]. It was demonstrated that the 
increased glycosylation status of Sp1 resulted in increased protein stability and 
enhanced its ability to bind DNA [83]. Conversely, it has been demonstrated by a 
number of investigators that phosphorylation of Sp1 targets the protein for 
degradation [84]. This is due to the phosphorylation occurring on PEST 
sequences or protein regions that are enriched in Pro, Glu, Ser, and Thr residues 
used as signals for the rapid degradation of proteins [85]. Many investigators 
have also shown that protein sequences modified by O-GlcNAc have high PEST 
sequences and therefore it has been proposed that this enhanced glycosylation 
can prevent phosphorylation of these PEST sequences and inhibit degradation 
[84]. In the context of affecting cholesterol synthesis, new studies have identified 
a novel mechanism by which maximal activation of the rat SREBP-1c gene by 
insulin requires Sp1 [86, 87]. Additionally, the presence of Sp1-binding motifs 
adjacent to an SRE (Sterol Regulatory Element) has been observed in the 
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promoters of a number of SREBP-responsive genes [88, 89]. Additional cis-
acting elements (e.g. SREBP, LXR, NF-Y) have been documented to play a role 
in insulin-activated SREBP-1c promoter through combinatorial actions [86]. In 
these thesis studies, I have focused on HBP-induced Sp1 glycosylation and its 
regulation on modulating transcription of cholesterol synthetic enzymes and PM 
cholesterol accrual in the development of insulin resistance.  
 
 The focus of my thesis work revolves around cellular and membrane 
changes in cholesterol amount in regards to cellular insulin action on glucose 
transport. As I have previously mentioned, there is a significant amount of work 
from our group demonstrating that insulin resistance conditions are a response to 
PM cholesterol accrual in both fat and skeletal muscle. We have also 
demonstrated that cholesterol-lowering can be a therapeutic target for slowing 
and possibly ceasing the progression from insulin resistance to type 2 diabetes. 
The cellular energy sensor, 5’ AMP-activated protein kinase (AMPK), is a target 
of one of the first-line anti-diabetic medications, metformin, that has been 
demonstrated to enhance glucose transport. Interesingly, AMPK is responsible 
for many other cellular actions including the inhibition of glycogenic and lipogenic 
processes. 
 
4. 5’-AMP Protein Kinase (AMPK) Cellular Actions 
 Classically, AMPK is a multimeric protein known as a cellular fuel gauge. 
Physiological activation of AMPK occurs when there is a rise in cellular AMP 
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concentration and a decrease in ATP concentration. Additionally, upstream 
activators of AMPK include a serine/threonine kinase, LKB1, as well as the 
Ca2+/Calmodulin-Dependent Kinase II (CaMKII) [90]. These proteins have been 
demonstrated to phosphorylate and activate AMPK on its Thr172 residue. Once 
activated AMPK has been demonstrated to affect a myriad of cellular activities 
including glucose transport, inhibition of fatty acid synthesis, and promoting fatty 
acid oxidation. Interestingly, AMPK activation is also associated with inhibition of 
cholesterol synthesis via phosphorylation of the rate-limiting enzyme in 
cholesterol biosynthesis, HMGR. AMPK has recently become a pharmacological 
target for patients with T2D. However, most of what is currently known on the 
importance of AMPK in peripheral insulin sensitivity was performed in skeletal 
muscle. The role of AMPK in adipose tissue is controversial with conflicting 
reports, some demonstrating that activation of the protein inhibits GLUT4 
translocation and glucose uptake [91] while other reports maintain that AMPK 
activity is beneficial to glucose transport [92] in this same cell type. 
 
4.1. AMPK Involvement in Anti-Diabetic Interventions 
 As mentioned earlier, an important result of cellular AMPK activation is the 
inhibition of energy-consuming processes such as lipid/cholesterol synthesis. 
Therefore, one could speculate the activation of this energy regulator could be 
used as a benefit for diabetic individuals through the decrease of detrimental 
cellular metabolic actions. It has been identified that a number of activators of 
AMPK have displayed benefits on correcting insulin resistance and enhancing 
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glucose transport. Although a mechanism is not fully understood, a widely held 
view is that AMPK increases insulin sensitivity. For example, several agents that 
normalize blood glucose concentrations and/or improve insulin action including 
the adipokines adiponection [93] and leptin [94], creatine [95], rosiglitazone [96], 
troglitazone [97], chromium picolinate (CrPic) [57], and alpha-lipoic acid [98] have 
been demonstrated to be the result of the activation of AMPK. Additionally, other 
identified activators of AMPK that display insulin-sensitizing actions have 
included exercise [99], newly identified nutritional supplements including 
berberine [100], and prescribed diabetic medications such as metformin [101]. 
Metformin has become one of the most popular and commonly prescribed 
medications for diabetic individuals. The actions of this drug have corrective 
benefits on hyperglycemia without stimulating insulin secretion, inducing weight 
gain, and causing hypoglycemia. Additionally, the actions of metformin have 
been far-reaching in that a decrease in circulating lipids associated with 
cardiovascular disease is witnessed with metformin treatment. Utilizing this 
background information and the ability of metformin to stimulate AMPK, it has 
been demonstrated that metformin is able to enhance glucose transport in L6 
myotubes in an insulin-independent fashion [102-104]. 
 
 Additional work from our laboratory [58] has tested the mechanism 
whereby exercise-induced glucose transport is mediated. This work placed 
AMPK as a central player in the benefits observed in a cell culture model of 
exercise. Using AICAR (an AMP analog) and 2,4-dinitrophenol (DNP, a 
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mitochondrial uncoupler that prevents cellular production of ATP) on L6 
myotubes, a significant enhancement of both basal and insulin-stimulated GLUT4 
translocation occurred concomitant with increased phosphorylation of AMPK. An 
unappreciated effect with the use of these AMPK activators that was also 
witnessed was a ~25% reduction in PM cholesterol. In several pilot studies, 
siRNA knockdown of the α-catalytic subunit of AMPK ablated the DNP-induced 
decrease in PM cholesterol compared to that of DNP treatment in siScramble 
myotubes. Taken together, these new findings regarding the AMPK activators, 
metformin and exercise-mimetic agents, support our hypothesis that a distal 
target/event of AMPK activation is PM cholesterol lowering.  
 
 Interestingly, work from our laboratory has demonstrated that the 
beneficial actions of a common nutritional supplement on glucose metabolism, 
chromium, are mediated by PM cholesterol lowering. Utilizing 3T3-L1 adipocytes, 
we have seen that this reduction of PM cholesterol is sufficient to enhance 
insulin-stimulated glucose transport by a pharmacologically relevant dose of 
chromium picolinate (CrPic). However, the mechanism by which CrPic-mediated 
reduction of PM cholesterol was still not understood allowing us to hypothesize 
that CrPic action may be a result of AMPK activation and its downstream 
inhibition of HMGR, the rate-limiting enzyme in cholesterol synthesis.   
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5. Chromium Supplementation in Health & Disease  
 In the late 1950s, chromium (Cr) was recognized in animals to be an 
essential nutrient required for normal glucose and lipid metabolism. Nutritional or 
trivalent chromium (Cr3+) is an essential mineral found in a multitude of foods, 
especially that of brewer’s yeast, meats, and whole-grain products. Additionally, 
health supplements are a significant and popular source of Cr3+ as evidenced by 
CrPic being the second highest-selling overall health supplement, only behind 
the sales of calcium supplements [105]. Its essentiality comes from the inability of 
humans to produce this mineral; therefore, the body must obtain Cr3+ through 
dietary sources. Unlike hexavalent chromium (Cr6+), a byproduct of stainless 
steel and pigment processing and classified as a human carcinogen, Cr3+ has 
been revealed to be stable and relatively non-toxic [106]. Ingestible Cr3+ can be 
found in a variety of forms, namely chromium yeast (CrY), chromium chloride 
(CrCl), and as the most stable and bioavailable supplement, chromium picolinate 
(CrPic).  
 
 Recent studies performed on the effects of Cr3+ have also designed and 
tested different pharmacologic compounds and complexes of Cr3+ such as 
chromium nicotinate (niacin, CrN), chromium (D-phenylalanine)3 (Cr(D-phe)3) 
and chromium citrate (CrC). Interestingly, all these complexes have been shown 
to have positive metabolic effects in the body and seem to be specific for Cr3+ 
compared to other minerals such as magnesium (Mg2+), manganese (Mn3+), and 
iron (Fe2+). The identification of Cr3+ as an essential nutrient was pioneered in 
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work by Schwarz and Mertz [107] where evidence was presented that an 
unidentified substance in brewer’s yeast protected rats from an age-related 
decline in glucose tolerance in 1957. The term coined for this substance was 
“glucose tolerance factor” or GTF. Shortly thereafter, GTF was actually 
recognized to be the nutrient, Cr3+. In 1977, it was observed that a 40 year old 
white female receiving total parenteral nutrition (TPN) for 5 years developed 
peripheral neuropathy, unexpected weight loss, and glucose intolerance as 
analyzed by an intravenous glucose tolerance test (IVGTT). She was given 
regular insulin and glucose infusions to restore her weight loss; however, her 
IVGTT remained remarkably unaffected. It was determined in this patient that her 
blood Cr3+ levels were extremely low (0.55 ng/ml) compared to a normal defined 
range between 4.9 and 9.5 ng/ml. Also, the patient’s hair Cr3+ levels were quite 
low (154 to 175 ng/g) compared to normal levels exceeding 500 ng/g. It was then 
recognized that her TPN was devoid of Cr3+ and after discontinuing her regular 
insulin infusions, the patient’s daily infusate was supplemented with 250 µg of 
Cr3+ for 2 weeks. Surprisingly, her glucose tolerance normalized. Subsequently in 
the next 5 months, regular insulin infusions were not needed and glucose 
infusions had to be dramatically reduced to avoid becoming overweight. During 
this 5-month period, her nerve conduction vastly improved suggesting that her 
peripheral neuropathy had subsided. Following regular maintenance of Cr3+ (20 
µg/day) levels, the patient remained well for 18 months [108]. Following this 
clinical observation, additional support for the essentiality of Cr3+ was offered 
when similar effects were witnessed in other hyperglycemic patients 
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supplemented with Cr3+ [109, 110]. Also, documentation exists that Cr3+ 
deficiency can result in defects associated with cardiovascular disease such as 
elevated serum cholesterol and triglycerides, and decreased high density 
lipoprotein cholesterol (HDL) [111, 112]. These clinical studies demonstrating 
pathologies associated with a Cr3+ deficiency prompted research pursuits into the 
mechanism of Cr3+ action on glucose and lipid metabolism. Although a precise 
mechanism(s) of Cr3+ action is still not known, in vitro and in vivo investigations 
highlight that Cr3+ indeed engages key cellular and molecular mechanisms that 
are regulatory for normal glucose and lipid metabolism. 
 
5.1. Chromium & Glucose/Lipid Disorders 
 Much like the case study presented above, encouraging findings in animal 
and human studies [113-115] have led many investigators to hypothesize that 
dietary Cr3+  supplementation may help to control T2D. Cr supplements are 
available as trivalent Cr in the chloride (CrCl3) or picolinate (CrPic) salt forms. 
Animal studies have shown that a deficiency in dietary Cr3+ can result in an 
inability to remove glucose efficiently from the bloodstream [116]. Evidence also 
suggests that diet-induced insulin resistance in experimental animals can be 
improved by Cr3+ supplementation [117]. In humans, there also seems to be an 
association between insulin resistance and Cr3+ status [118].  
 
 The exact mechanism whereby Cr3+ participates in the functions of insulin 
has not been elucidated, but theories range from direct interaction of Cr3+ with 
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insulin [119] to a role of Cr3+ in increasing IR number [120], as well as increasing 
IR tyrosine kinase activity already engaged by insulin [121]. It has been 
demonstrated that a naturally occurring oligopeptide, low-molecular weight Cr-
binding substance (termed “chromodulin”) binds chromic ions in response to an 
insulin-stimulated IR, activating the receptor’s tyrosine kinase activity as much as 
8-fold in the presence of insulin [121, 122]. The chromodulin-mediated 
autoamplification of the IR’s tyrosine kinase activity would be expected to 
enhance the regulated movement of GLUT4 and, subsequently, enhance 
glucose disposal. This anticipated biological outcome has been observed [115], 
but signaling molecules responsible for the translocation have not yet been 
evaluated.  
 
 Another aspect of Cr3+ action that may explain, at least in part, its 
enhancement of insulin sensitivity is its effect on increasing membrane fluidity 
and the rate of insulin internalization [123]. Although insulin-stimulated GLUT4 
translocation does not appear dependent upon insulin first being transported into 
the cell [124], studies suggest that IR internalization may compartmentalize and 
efficiently promote interaction with its substrate(s) associated with internal 
membranes [125-127]. In agreement with membrane fluidity changes as a basis 
for the effect of Cr3+, moderate increases in PM fluidity have been documented to 
increase glucose transport [128, 129]. Furthermore, it has been shown that basal 
glucose transport is not fully active in fat cells and that it can be increased further 
by augmenting membrane fluidity [128]. Consistent with membrane fluidity 
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influencing insulin responsiveness, insulin-stimulated glucose transport is 
decreased when fluidity diminishes [129]. Interestingly, recent data suggest that 
the antidiabetic drug metformin enhances insulin action by increasing membrane 
fluidity [130, 131]. As has been observed after Cr3+ treatment [115], metformin 
treatment has been reported to increase GLUT4 translocation [65, 103, 132]. 
Work presented in this thesis demonstrated that the beneficial effects of Cr3+ on 
insulin action resulted from changes in PM properties. These data demonstrated 
that PM cholesterol content was diminished in cells exposed to Cr3+ and that 
exogenous cholesterol replenishment rendered the enhancement of insulin 
action by Cr3+ ineffective.  
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Overview of Proposed Mechanism(s) of Cellular GLUT4 Translocation. 
Above figure depicts insulin signaling proteins (black) involved in the 
translocation of intracellular GLUT4 storage vesicles to the plasma membrane. 
Depicted on the right hand side of the figure is the result of work from our 
laboratory demonstrating the interconnection between cholesterol, PIP2, and 
cortical F-actin in insulin-stimulated GLUT4 translocation. An insulin-independent 
mechanism involving AMPK is also shown (grey boxes) and its downstream 
effects such as inhibition of ACC and HMGR as well as stimulation of GLUT4 
translocation to the PM.  
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Hypothesis/Summary of Proposed Mechanism 
  Throughout my thesis studies, the main hypothesis tested was that 
perturbations in the PM was a contributory factor to the development of insulin 
resistance and pharmacologic and nutritional agents designed to correct these 
PM defects would then result in normalized insulin sensitivity and GLUT4 
translocation. As outlined in Chapter II, the testing of this hypothesis resulted in 
three main parts. My studies began with hyperinsulinemia-induced disturbances 
of GLUT4 translocation through changes in PIP2 and cortical F-actin which was 
tested in Chapter IIA. Subsequently, Chapter IIB outlines the results of testing 
demonstrating that chromium action was a result of PM cholesterol lowering and 
enhancement of GLUT4 translocation. Finally, the results presented in Chapter 
IIC exhibited that increased HBP activity, as a result of hyperinsulinemia or 
hyperglycemia, contributed to the alterations in the PM PIP2 and cortical F-actin. 
Interestingly, preliminary studies that were undertaken throughout suggested that 
increased HBP activity resulted in PM cholesterol accrual via alterations in the 
transcriptional activity of cholesterol synthetic enzymes. 
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Chapter II 
 
Results 
 
 
II. A 
Protective Effect of Phosphatidylinositol 4,5-Bisphosphate Against Cortical 
Filamentous Actin Loss and Insulin Resistance Induced by Sustained 
Exposure of 3T3-L1 Adipocytes to Insulin 
 
1. Summary 
 
 Muscle and fat cells develop insulin resistance when cultured under 
hyperinsulinemic conditions for sustained periods. Recent data indicate that early 
insulin signaling defects do not fully account for the loss of insulin action. Given 
then cortical filamentous actin (F-actin) represents an essential aspect of insulin 
regulated glucose transport, we tested to see whether cortical F-actin structure 
was compromised during chronic insulin treatment. The acute effect of insulin on 
GLUT4 translocation and glucose uptake was diminished in 3T3-L1 adipocytes 
exposed to a physiological level of insulin (5 nM) for 12 h. This insulin-induced 
loss of insulin responsiveness was apparent under both low (5.5 mM) and high 
(25 mM) glucose concentrations. Microscopic and biochemical analyses revealed 
that the hyperinsulinemic state caused a marked loss of cortical F-actin. Since 
recent data link phosphatidylinositol 4,5-bisphosphate (PIP2) to actin cytoskeletal 
mechanics, we tested to see whether the insulin-resistant conditions affected 
 36 
PIP2 and found a noticeable loss of this lipid from the plasma membrane. Using a 
PIP2 delivery system, we replenished plasma membrane PIP2 in cells following 
the sustained insulin treatment and observed a restoration in cortical F-actin and 
insulin responsiveness. These data reveal a novel molecular aspect of insulin-
induced insulin ressistance involving defects in PIP2/actin regulation.  
 
2. Results 
 
Insulin-stimulated GLUT4 translocation is impaired by chronic insulin 
treatment  
The generation of insulin resistance by exposure of 3T3-L1 adipocytes to 
a medium containing a high concentration of glucose and insulin has been well 
documented [66, 67, 133]. In our initial experiments, 3T3-L1 adipocytes 
preincubated in control medium (25 mM glucose) exhibited a marked response to 
an acute maximal dose of insulin (30’ Ins) as assessed by GLUT4 
immunofluorescence of highly purified PM sheets (Fig. 1A, compare panels 1 
and 3). On the other hand, the presence of a physiological dose of insulin (5 nM) 
for 12 h was associated with an elevation of PM GLUT4 in the basal state and a 
clear loss in the acute maximal insulin-stimulated GLUT4 translocation (Fig. 1A, 
compare panels 2 and 4). To confirm the accumulation of GLUT4 in the PM 
sheets, we used differential centrifugation to isolate PM fractions. Fractions 
prepared from control 3T3-L1 adipocytes displayed a characteristic insulin-
stimulated increase in GLUT4 compared with PM fractions prepared from 
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untreated cells (Fig. 1B, compare lanes 1 and 2). Consistent with microscopic 
analyses, the immunoblots showed that chronic insulin treatment was associated 
with an elevation of the basal stae PM GLUT4 level and a loss in the insulin 
stimulated increment above the basal (Fig. 1B, compare lanes 1-4). 
Densitometry analysis of four separate experiments shows that sustained insulin 
exposure tended to increase (p=0.08) the basal state PM level of GLUT4 and 
attenuate insulin-stimulated GLUT4 translocation by 42% (p < 0.05).  
 38 
Fig. 1 Chronic Insulin Treatment Impairs Subsequent Acute Insulin 
Stimulated GLUT4 Translocation. Adipocytes were treated for 12 h in the 
absence (Control) or presence of 5 nM insulin (12 h Ins). Following this 
incubation period, cells were washed and stimulated with 100 nM insulin for 30 
min (30’ Ins) or left in the basal state (Basal). (A) PM sheets were prepared and 
subjected to immunofluorescent GLUT4 labeling. All microscopic and camera 
settings were identical between groups, and representative images from five to 
eight independent experimnts are shown. (B) plasma membrane fractions were 
prepared, resolved on a 10% polyacrylamide gel, and subjected to Western 
blotting with GLUT4 antibody. (C) densitometric quantification (±S.E., *, p<0.05) 
of the three independent Western blotting analyses.  
  
A) IF:GLUT4
B) IB:GLUT4
C)
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Prolonged Insulin Treatment Reduces Cell Surface PIP2 and Actin Levels 
There are several possible mechanisms that could account for the 
decreased insulin-stimulated GLUT4 translocation by the hyperinsulinemia. 
However, consistent with previous work [134, 135], known proximal insulin signal 
transduction events including the IR autophosphorylation, IRS-1, and Akt 
phosphorylation were not significantly different between 3T3-L1 adipocytes 
maintained in control medium with or without 5 nM insulin (data not shown). 
Because the proximal insulin signaling cascades appeared to be fully functional, 
we next examined the effect of high glucose/insulin on cortical F-actin. Chronic 
insulin led to a marked reduction in cortical F-actin as assessed with phalloidin 
staining of fixed whole cells (Fig. 2A, compare panels 1 & 2). Red fluorescent co-
staining of nucleic acids with propidium iodide was employed to verify the 
presence of cells (Fig. 2A, compare panels 1-3). Actin staining was verified in 
cells with latrunculin B (Lat B, an actin monomer binding toxin) treatment (Fig. 
2A, panel 3). In addition, F-actin to G-actin ratio determination by Western 
immunoblot analysis confirmed that cells incubated overnight in 5 nM insulin 
undergo a marked reduction in F-actin and an increase in G-actin, consistent with 
an induced depolymerization of cortical F-actin (Fig. 2B). Since recent data link 
PIP2 to actin cytoskeletal regulation [136], we next tested whether this insulin-
resistant condition affected PIP2. The level of plasma membrane PIP2 was 
markedly reduced by 5 nM insulin treatment as assessed by anti-PIP2 
immunofluorescent labeling of plasma membrane sheets (Fig. 2C, panels 1 & 2). 
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The immunoreactivity of the anti-PIP2 antibody was confirmed in cells in which 
PIP2 levels were reduced by LiCl treatment (Fig. 2C, panel 3). 
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Fig. 2 Cellular Cortical F-actin and PM PIP2 Levels are Diminished in Cells 
Treated with Insulin for 12 h. Adipocytes were treated as described in the 
legend to Fig.1. (A) nucleic acids and actin in whole cells were co-stained with 
propidium iodide (red) and phalloidin (green), respectively. A subset of cells co-
labeled the same way presented in panel 3 were treated with latrunculin B. 
Representative images from four independent experiments are shown. (B) F- 
and G-actin fractions were prepared, resolved on a 12% polyacrylamide gel, and 
subjected to Western blotting with actin antibody. Densitometric quantification 
(±S.E., *, p<0.05) derived from three independent experiments are shown. (C) 
membrane sheets were labeled for PIP2. Sheets, derived from cells treated with 
10 mM LiCl, are presented in panel 3. Representative images from five 
independent experiments are shown.  
  
A) Actin
B) F-/G-Actin
C) PIP2
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The Loss of PIP2, Actin, and Insulin Sensitivity is Restored with PIP2 
Replenishment  
Carrier delivery of PIP2 into insulin-resistant adipocytes led to a dose-
dependent replenishment of PIP2 (Fig. 3A, panels 1, 3, 5, 7, and 9) and cortical 
F-actin (Fig. 3A, panels 2, 4, 6, 8, and 10). Complete restoration of both PIP2 
and cortical F-actin was apparent with a PIP2 addback concentration of 1.25 µM. 
Thus, we used this concentration to directly test whether the impairment in insulin 
action occurred as a result of the chronic insulin-induced losses of PIP2 and 
cortical F-actin. A characteristic increase in insulin-stimulated GLUT4 
translocation as assessed by the sheet assay was observed in cells incubated 
with carrier alone (Fig. 3B, panels 1 and 4). Carrier alone did not change the 
negative consequence of overnight insulin treatment on acute insulin-stimulated 
GLUT4 translocation (Fig. 3B, panels 2 and 5). Remarkably, acute insulin-
stimulated GLUT4 translocation in adipocytes rendered insulin resistant was 
concomitantly restored by 1.25 µM PIP2 replenishment (Fig. 3B, panels 3 and 6). 
In concert with our findings presented in Fig. 1, we also observed a slight 
increase in the basal state PM level of GLUT4 under hyperinsulinemic conditions 
(Fig. 3B, compare panels 1 and 2). Interestingly, we consistently observed that 
this increase in transporter was reduced by PIP2 replenishment (Fig. 3B, 
compare panels 1-3). Parallel examination of 2-deoxyglucose uptake showed a 
concomitant loss of insulin-stimulated glucose transport in cells preincubated in 
the presence of insulin compared with cells that were not (Fig. 3C). In line with 
previously published work [66, 67, 137], the hyperinsulinemic condition was not 
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associated with a statistically significant increase in basal glucose transport. 
Consistent with PIP2 correction of insulin action, the reduced insulin-stimulated 
glucose transport was restored with PIP2 replenishment (Fig. 3C). Given that our 
control medium contained 25 mM glucose and the combination of high glucose 
with insulin has been suggested to be the cause of the insulin resistant state [66, 
67], we also examined the effect of hyperinsulinemia on cells incubated in a low 
glucose medium (5.5 mM Glc). Insulin acutely increased GLUT4 translocation in 
cells cultured in low glucose medium (Fig. 3D, compare panels 1 and 4), and the 
extent of PM-associated GLUT4 was qualitatitively equivalent with that induced 
acutely by insulin in cells cultured in high glucose media (Fig. 3B, compare 
panels 1 and 4), as reported previously [67]. Cells cultured in low glucose in the 
presence of 5 nM insulin for 12 h displayed an increase in the basal state PM 
level of GLUT4 and a marked reduction in the ability of insulin to acutely 
stimulate GLUT4 translocation (Fig. 3D, compare panels 2 and 5). The effect of 
chronic insulin on insulin sensitivity in cells cultured in low glucose was strikingly 
similar to that in cells cultured in high glucose medium and further analyses also 
revealed a chronic insulin-induced loss of PM PIP2 in these cells (data not 
shown). Accordingly, acute insulin-stimulated GLUT4 translocation in adipocytes 
cultured in low glucose medium rendered insulin resistant by chronic insulin was 
concomitantly restored by 1.25 µM PIP2 replenishment (Fig. 3D, panels 3 and 6). 
As observed in cells cultured in high glucose, the chronic insulin-induced 
augmentation of PM GLUT4 was reduced upon PIP2 addback (Fig. 3D, panel 3). 
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Taken together, these data suggest that the PIP2-dependent insulin resistant 
state was independent of glucose load. 
Interestingly, the work presented in this section offered an interesting 
observation to our laboratory in that increasing cellular glucose flux was a key 
mediator of insulin resistance. In parallel, my research interests lied in the 
mechanism by which anti-diabetic therapies may enhance glucose transport in 
these tissues. In accord with these research interests, our laboratory was 
beginning to study the mechanism by which the essential nutrient chromium was 
beneficial in diabetic patients. Much like the development of insulin resistance as 
an effect of changes in glucose flux, work that will be presented below 
demonstrated that chromium action was dependent on PM cholesterol lowering 
in adipocytes that were only cultured in high glucose medium.  
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Fig. 3 Diminished Cortical F-actin and Insulin-Stimulated GLUT4 
Translocation in Cells Treated with Chronic Insulin are Corrected by PIP2 
Replenishment. (A-C) cells were treated overnight in the absence (Control) or 
presence of 5 nM insulin for 12 h. (A) during the last 60 min of the 12 h period, 
the medium was replaced with the same medium enriched with either histone H1 
(panels 1-4) or indicated concentrations of PIP2/histone H1 (panels 5-10). PM 
sheets (panels 1, 3, 5, 7, and 9) or whole cells (panels 2, 4, 6, 8, and 10) were 
labeled for PIP2 (red) and actin (green), respectively. (B) histone H1 (panels 1, 2, 
4, and 5) or 1.25 µM PIP2 (panels 3 and 6) addback incubations were performed 
as described. (C) 2-[3H]deoxyglucose (2-DG) uptake was determined as 
described. (D) cells cultured in 5.5 mM glucose were treated overnight in the 
absence (5.5 Glc) or presence of 5 nM insulin (5.5 Glc/12 h Ins) for 12 h. 
  
A)
PIP2 Actin
B) IF:GLUT4
C) Glucose Transport
D) IF:GLUT4
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II. B 
 
Chromium Activates GLUT4 Trafficking and Enhances Insulin-Stimulated 
Glucose Transport in 3T3-L1 Adipocytes Cultured Under Hyperglycemic 
Diabetic Conditions via a Cholesterol-Dependent Mechanism 
 
1. Summary 
 
Evidence suggests that chromium supplementation may alleviate 
symptoms associated with diabetes, such as high blood glucose and lipid 
abnormalities, yet a molecular mechanism remains unclear. We have found that 
exposure of 3T3-L1 adipocytes to a pharmacologically-relevant dose (10 nM) of 
chromium picolinate (CrPic) or chromium chloride (CrCl3) mobilizes the glucose 
transporter, GLUT4, to the plasma membrane (PM). Since CrPic is the most 
popular supplemental form of Cr3+, my thesis studies focused on the actions of 
CrPic rather than the less bioavailable and less popular CrCl3. Accumulation of 
intracellularly sequestered GLUT4 at the PM by CrPic was dependent on PM 
cholesterol reduction consistent with a previously published report demonstrating 
that chromium increases membrane fluidity. Concomitant with an increase in 
GLUT4 at the PM, insulin-stimulated glucose transport was enhanced by Cr3+ 
treatment. Regulation of GLUT4 translocation by CrPic did not involve known 
insulin signaling proteins such as the IR, IRS-1, PI3K, and Akt.  
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 Although CrPic supplementation has been shown to be preventative in the 
development of diabetes in otherwise healthy individuals, the actual benefits of 
CrPic supplementation on glucose metabolism solely occur in hyperglycemic, 
insulin-resistant individuals. Using our 3T3-L1 cell culture system, we tested 
whether the CrPic effect on cells was glucose-dependent. We found that GLUT4 
redistribution in adipocytes treated with CrPic occurred only in cells cultured 
under 25 mM glucose conditions (HG; high glucose), which resemble a poorly-
controlled diabetic individual, and not in cells cultured under non-diabetic 5.5 mM 
glucose conditions (LG; low glucose). As previously mentioned, this GLUT4 
translocation event by CrPic occurred as a result of PM cholesterol reduction in 
HG adipocytes alone. Examination of the effect of CrPic on proteins involved in 
cholesterol homeostasis revealed that the activity of SREBP, a membrane-bound 
transcription factor ultimately responsible for controlling cellular cholesterol 
balance, was upregulated by CrPic. In addition, ATP-binding cassette A1 
(ABCA1), a major player in mediating cholesterol efflux was decreased. Although 
the exact mechanism of CrPic-induced cholesterol loss remains to be 
determined, these cellular responses highlight a novel and significant effect of 
Cr3+ on cholesterol homeostasis.  
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2. Results 
 
Cr3+ triggers the redistribution of GLUT4 to the plasma membrane in 
adipocytes 
Our preliminary treatment parameters were selected based on in vitro data 
showing trivalent Cr in the chloride and picolinate salt formulations, ranging from 
1 mM to 20 mM, enhanced glucose uptake and membrane fluidity in cultured 
mouse and rat skeletal muscle cells [123, 138]. Incubation of 3T3-L1 adipocytes 
with 10 µM CrCl3 or 10 µM CrPic for 16 h increased the basal and insulin-
stimulated level of GLUT4 in the plasma membrane as assessed by GLUT4 
immunofluorescence of highly purified plasma membrane sheets (Fig. 4A). 
Digital image processing showed the basal-state plasma membrane levels of 
GLUT4 following CrCl3 and CrPic pretreatments were increased 44% (p<0.001) 
and 35% (p<0.001), respectively. The insulin-stimulated plasma membrane level 
of GLUT4 was increased 151% (p<0.005) and this stimulation was amplified by 
both CrCl3 and CrPic pretreatments by 43% (p<0.05) and 39% (p<0.05), 
respectively. To confirm the effect of Cr3+ on the accumulation of GLUT4 in 
isolated plasma membrane sheets, we used differential centrifugation to isolate 
plasma membrane from 3T3-L1 adipocytes. Plasma membrane fractions 
prepared from cells treated with insulin displayed a characteristic increase in 
GLUT4 compared with plasma membrane fractions prepared from untreated cells 
(Fig. 4B, compare lanes 1 and 2). Consistent with the microscopic analysis, 
immunoblot analysis showed that Cr3+ treatment for 16 h increased the basal-
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state level of GLUT4 in the plasma membrane (Fig. 4B, compare lanes 1, 3 and 
5), and the insulin effect was enhanced in the presence of Cr3+ (Fig. 4B, 
compare lanes 2, 4 and 6). A constant finding with plasma membrane 
preparation via subcellular fractionation (Fig. 4B) was the chromium-induced 
increase in the basal-state plasma membrane level of GLUT4 was similar to that 
induced by insulin alone; whereas, this was not the case in isolated plasma 
membrane sheets where the chromium effect on the basal-state plasma 
membrane level of GLUT4 was less than that of insulin. In contrast to plasma 
membranes obtained with the “sheet” assay, which are highly purified, the 
fractions isolated by centrifugation are likely contaminated, to some extent, with 
cytosol and intracellular vesicles [139]. Therefore, although chromium appears to 
be mobilizing GLUT4 to the plasma membrane, the majority of it may not be 
physically incorporated into the cell surface. Nonetheless, these microscopic and 
biochemical data clearly show that chromium elicits an insulin-like accumulation 
of GLUT4 at the plasma membrane in 3T3-L1 adipocytes. As shown in Fig. 4C, 
this accumulation elicited by CrPic treatment occurs concomitant with a loss of 
GLUT4 protein in the low density microsome (LDM) fraction. Also, Cr3+ treatment 
did not affect total GLUT4 protein levels detected in crude total membrane (CM) 
fractions (Fig. 4D). 
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Fig. 4 Cr3+ stimulates GLUT4 translocation. 3T3-L1 adipocytes were treated 
with 10 µM CrCl3 or 10 µM CrPic in serum-free DMEM for 16 hours. During the 
last 30 min of incubation, the cells were either left unstimulated (Basal) or 
stimulated with 1 nM insulin. (A) Representative plasma membrane (PM) sheet 
GLUT4 images are shown from 5-8 experiments. (B) PM, (C) low density 
microsome (LDM), and (D) crude membrane (CM) fractions immunoblotted (IB) 
for GLUT4. These are representative immunoblots (IB) from 3-5 independent 
experiments. 
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Key insulin signal transduction events are not stimulated by Cr3+ 
There are several possible mechanisms that could account for the 
increased GLUT4 translocation by Cr3+. We first explored whether known 
proximal insulin signal transduction events including insulin receptor (IR) 
autophosphorylation, insulin receptor substrate-1 (IRS-1) and Cbl tyrosine 
phosphorylation, and Akt phosphorylation were involved. Given that the most 
popular form of chromium in dietary supplements is CrPic [140], here and most of 
the subsequent analyses aimed at understanding the molecular mechanism of 
Cr3+ action used CrPic. Insulin stimulation resulted in increased tyrosine 
phosphorylation of the IR β-subunit, IRS-1 and Cbl at 5 min (Figs. 5A, 5B, and 
5C, compare lanes 1 and 3) or at 2-, 15-, 30-min treatment intervals (data not 
shown). In contrast to the effect of insulin, the overnight CrPic pretreatment 
associated with insulin-like activity had no effect on the phosphorylation of these 
proteins in the absence or presence of insulin (Figs. 5A, 5B, and 5C, compare 
lanes 1 and 2, and 3 and 4). Immunoblotting of those same membranes with anti 
IR β-subunit, IRS-1, and Cbl antibodies demonstrated the presence of equal 
amounts of IR β-subunit, IRS-1 and Cbl (Figs. 5A, 5B, and 5C, lanes 5-8). In 
addition to immunoblotting cell lysates, we immunoblotted IR, IRS-1, and Cbl 
immunoprecipitates and these data confirmed that insulin, but not CrPic, 
increased the extent of tyrosine phosphorylation of these proteins (data not 
shown). 
 Although the signaling events distal to the Cbl cascade remain unclear, 
recognized molecules of the IRS-1 cascade involved in GLUT4 translocation are 
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PI3K and the Akt serine/threonine kinase. Akt-1 phosphorylation, which is 
indicative of activation, was assessed by using an anti-phospho-Ser473 antibody 
that is specific for the serine phosphorylated Akt-1 isoform, whereas the 
phosphorylation of Akt-2 was determined by monitoring the mobility shift 
indicative of the phosphorylated and active enzyme [141]. Insulin stimulated the 
phosphorylation of both Akt-1 (Fig. 5D, left immunoblot, compare lanes 1 and 3) 
and Akt-2 (Fig. 5D, right immunoblot, compare lanes 5 and 7). In contrast, 
exposure of cells to CrPic did not result in phosphorylation of either Akt isoform 
(Fig. 5D, compare lanes 1 and 2, and 5 and 6) or increase insulin’s effect on 
these kinases (Fig. 5D, compare lanes 3 and 4, and 7 and 8). 
 To further assure ourselves that the classical insulin signaling pathway 
was not a target of Cr3+ action we sought to test the effect of phosphatidylinositol 
3-kinase (PI3K) inhibition on CrPic action. However, testing the role of PI3K with 
the PI3K inhibitors wortmannin or LY294002 was complicated by the 16 h CrPic 
treatment. Moreover, since PI3K regulates endocytosis, a wortmannin-induced 
loss of CrPic action may reflect a loss of the endocytic uptake of CrPic and not 
CrPic-stimulated PI3K signaling. To circumvent these issues and assess the 
effect of CrPic on PI3K activity we evaluated phosphatidylinositol 3,4,5-
trisphosphate (PIP3) generation as we have previously reported [142]. Using a 
specific PIP3 antibody [143, 144], microscopic analyses revealed very little 
endogenous PIP3 localized at the plasma membrane in the absence or presence 
of CrPic treatment (Fig. 5E, panels 1 and 2). Strong nuclear PIP3 labeling was 
observed in all cells (Fig. 5E), as previously documented [145]. Consistent with 
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PI3K activation by insulin, an increase in plasma membrane PIP3 was apparent 
in insulin-stimulated cells (Fig. 5E, panel 3), an amplification of this by CrPic 
exposure was not evident (Fig. 5E, compare panels 3 and 4). 
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Fig. 5 Cr3+ treatment does not enhance basal or insulin-stimulated 
phosphorylation states of the insulin receptor β-subunit, IRS-1, Cbl, PI3K, 
or Akt. 3T3-L1 adipocytes were left untreated (lanes 1 and 3) or treated with 10 
mM CrPic (lanes 2 and 4) in serum-free DMEM for 16 hours. During the last 5 
min of incubation, the cells were either left unstimulated (Basal) or stimulated 
with 1 nM insulin. Whole-cell detergent lysates were generated and subjected to 
immunoblotting with antibodies to (A and B) phosphotyrosine (left immunoblots, 
lanes 1-4), (A) IRβ (right immunoblot, lanes 5-8), (B) IRS-1 (right immunoblot, 
lanes 5-8), (C) P(Tyr) c-Cbl (left immunoblot, lanes 1-4) and Cbl (right 
immunoblot, lanes 5-8), and (D) P(Ser)Akt (left immunoblot, lanes 1-4) and Akt-2 
(right immunoblot, lanes 5-8) as described in Materials and Methods. These are 
representative immunoblots from 3 separate experiments. (E) Shown are 
representative images of whole cell PIP3 from 3 independent experiments. 
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Cr3+-induced GLUT4 translocation is coupled to plasma membrane 
cholesterol loss 
Recently, we reported that moderate cholesterol depletion from the 
plasma membrane increases the basal-state plasma membrane level of GLUT4 
[141]. Given that Cr3+ has been demonstrated to influence membrane fluidity 
[146], we next evaluated whether the insulin mimetic action of Cr3+ may be 
coupled to changes in plasma membrane properties, in particular, cholesterol 
content. Exposure of the cells to CrPic for 16 h resulted in a 29% loss (p<0.05) of 
plasma membrane cholesterol (Fig. 6A). This loss of cholesterol from the plasma 
membrane prompted us to ask whether Cr3+-induced GLUT4 translocation could 
be prevented by restoring the basal-state plasma membrane level of cholesterol. 
Here we used methyl-β-cyclodextrin (βCD) preloaded with cholesterol as we 
have previously reported [141] to replenish the depleted plasma membrane 
cholesterol. The reduction in plasma membrane cholesterol induced by CrPic 
treatment was prevented in cells incubated in medium enriched with βCD 
preloaded with cholesterol (βCD:Chol) (Fig. 6A). The effect of βCD:Chol did not 
significantly alter the basal-state level of cholesterol content in the plasma 
membrane (Fig. 6A). The ability of CrPic to mobilize GLUT4 to the plasma 
membrane was prevented in cells incubated in βCD:Chol (Fig. 6B, compare 
panels 2 and 4) and the effect of βCD:Chol did not alter the basal-state level of 
GLUT4 in the plasma membrane (Fig. 6B, compare panels 1 and 3). These 
findings are consistent with previous work by our group [141] showing that 
reduction in plasma membrane cholesterol activates GLUT4 translocation.  
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Fig. 6 Cr3+ diminishes plasma membrane cholesterol and cholesterol 
replenishment prevents Cr-induced GLUT4 translocation. 3T3-L1 adipocytes 
were left untreated (-CrPic, panels 1 and 3) or treated with 10 mM CrPic (+CrPic, 
panels 2 and 4) in serum-free DMEM for 16 hours, which did not (panels 1 and 2) 
or did contain (panels 3 and 4) 1 mM bCD preloaded with cholesterol. (A) Cells 
were harvested, plasma membrane fractions were prepared, and membrane 
cholesterol content was determined as described under Materials and Methods. 
Results are expressed as percent of control. They represent the mean (± SE, * 
P<0.05) from 3-4 independent experiments. (B) Representative plasma 
membrane (PM) sheet GLUT4 images are shown from 3 experiments. 
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 To further explore this cholesterol-dependency of Cr3+ action, we next 
tested if the Cr3+ effect would be compromised in cells where membrane 
cholesterol was depleted by βCD pretreatment. As shown in Fig. 7A, exposure of 
3T3-L1 adipocytes to 1.0 mM βCD for a total of 16.5 hr lowered plasma 
membrane cholesterol by 20% (p<0.05). Consistent with our previous findings, 
this βCD-induced loss of plasma membrane cholesterol was associated with an 
increase in basal (Fig. 7B, compare panels 1 and 2) and insulin-stimulated (Fig. 
7B, compare panels 4 and 5) GLUT4 translocation. As shown in Fig. 6, CrPic 
treatment (16.5 hr) in this experiment lowered plasma membrane cholesterol and 
increased GLUT4 translocation to the same extent as 1.0 mM βCD (data not 
shown). Interestingly, no further reduction in plasma membrane cholesterol was 
observed in βCD -treated cells exposed to CrPic (Fig. 7A). Consistent with Cr3+ 
action being cholesterol-dependent, no further augmentation of plasma 
membrane GLUT4 was observed in cells co-treated with βCD and CrPic (Fig. 
7B, panels 3 and 6). 
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Fig. 7. Cells with a βCD-induced moderate cholesterol loss are 
unresponsive to Cr3+. Cells were pretreated without or with 1 mM βCD for 30 
min and then left untreated or treated with 10 mM CrPic in serum-free DMEM in 
the continual presence of βCD for 16 hours. Following this 16.5 hr period cells 
were either left untreated or treated with 1 nM insulin for 30 min. (A) Membrane 
cholesterol was determined and is presented as described in preceding legend. 
They represent the mean (± SE, * P<0.05) from 3 independent experiments. (B) 
Representative plasma membrane (PM) sheet GLUT4 images are shown from 3 
experiments. 
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Finally, since CrPic treatment was not associated with an amplification of 
the insulin signal (Fig. 5), we assessed whether the augmented action of insulin 
to stimulate glucose transport in the presence of a pharmacologic dose of CrPic 
(10 nM) was due to the cholesterol-dependent increase in GLUT4 at the cell 
surface. Fig. 8 shows that this pharmacological dose of CrPic significantly 
decreased the basal-state plasma membrane level of cholesterol. The reduction 
in plasma membrane cholesterol induced by CrPic treatment was prevented in 
cells incubated in medium enriched with βCD:Chol (Fig. 8A). The effect of 
βCD:Chol did not significantly alter the basal-state plasma membrane level of 
cholesterol (Fig. 8A). Consistent with the beneficial effect of CrPic on insulin 
action being due to the cholesterol-dependent mobilized pool of GLUT4, the 
ability of CrPic to enhance insulin-stimulated glucose transport was prevented in 
cells incubated in βCD:Chol (Fig. 8B). Also, βCD:Chol alone did not alter basal 
and insulin-stimulated glucose transport. 
  
 60 
Fig. 8 Cr3+-enhanced insulin-stimulated glucose transport is cholesterol-
dependent. 3T3-L1 adipocytes were pretreated in the absence (-) or presence 
(+) of 10-8 M CrPic for 16 hr in serum free media which did not (-) or did contain 
(+) 1 mM βCD preloaded with cholesterol. (A) Cells were harvested, plasma 
membrane fractions were prepared, and membrane cholesterol content was 
determined as described under Materials and Methods. Results are expressed 
as percent of control. They represent the mean (± SE, * p<0.05) from three 
independent experiments. (B) Glucose transport was determined by specific 
uptake of 2-[3H]deoxyglucose as described under Materials and Methods. All 
insulin-stimulated uptakes were significantly (p<0.001) elevated over their 
respective controls. (*p<0.05 versus all other groups). 
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Insulin Mimetic Activity of CrPic is Cholesterol-Dependent 
 In the work presented above, it was discovered that both CrPic and CrCl3 
at concentrations as low as 10 nM stimulated the mobilization of GLUT4 to the 
plasma membrane of 3T3-L1 adipocytes [57]. A novel observation was that this 
redistribution of GLUT4 was dependent on a Cr3+-induced loss of plasma 
membrane cholesterol. Although these data are consistent with Cr3+ exerting a 
positive effect on the glucose transport system and lowering elevated blood 
glucose in type 2 diabetic individuals, a confounding issue is that non-diabetic 
individuals do not experience a change in blood glucose following CrPic 
treatment. Since the standard medium used to culture 3T3-L1 adipocytes 
contains 25 mM glucose, a concentration of glucose akin to that in a poorly 
controlled diabetic individual, we tested if the cellular response to Cr3+ treatment 
would be diminished in cells cultured in a normal level of glucose (5.5 mM).  
 
 Consistent with an enhancing effect of CrPic on GLUT4 translocation in 
cells cultured in 25 mM glucose, plasma membrane fractions from these cells 
displayed an increase in GLUT4 compared with plasma membrane fractions 
prepared from untreated cells (Fig. 9, compare lanes 1 and 2). Interestingly, the 
same treatment parameters did not increase the basal-state plasma membrane 
level of GLUT4 in cells cultured in medium containing 5.5 mM glucose (Fig. 9, 
compare lanes 3 and 4). With our previous observations that CrPic action 
requires changes in plasma membrane cholesterol, we next compared the 
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plasma membrane cholesterol levels in the high glucose (CrPic-sensitive) and 
low glucose (CrPic-resistant cells).  
 
 Fig. 9B shows that plasma membrane fractions prepared from cells 
cultured in 25 mM glucose were more cholesterol enriched by 13% (p<0.05) than 
membranes prepared from cells cultured in 5.5 mM glucose, and CrPic 
selectively lowered this excess cholesterol only in the “high glucose” cells by 
18% (p<0.05). Notably, cells cultured in 5.5 mM glucose contain a similar level of 
plasma membrane cholesterol to those cultured in 25 mM glucose/10 nM CrPic, 
and treatment of the low-glucose cultured cells tended to increase plasma 
membrane cholesterol, but this was not statistically significant. Therefore, we 
next confirmed if addition of exogenous cholesterol in the culture medium 
prevented CrPic action. As previously reported [56, 57], this experimental 
manipulation that replenished the reduced cholesterol effectively prevented the 
translocation of GLUT4 to the plasma membrane elicited by CrPic (Fig. 9C).  
 63 
Fig. 9 GLUT4 translocation and cholesterol loss stimulated by CrPic in cells 
cultured in high, but not low, glucose containing medium. 3T3-L1 adipocytes 
were left untreated or treated with 10 nM CrPic in serum-free DMEM containing 
25 mM glucose (Glc) or 5.5 mM Glc for 16 hours. Shown are (A) GLUT4 
immunoblot (IB) and (B) cholesterol content of plasma membrane (PM) fractions 
prepared by ultracentrifugation as described in Material and Methods. (C) 
Quantitated GLUT4 content in PM fragments prepared by sonication as 
described in Material and methods from cells left untreated or treated with 10 nM 
CrPic in serum-free DMEM containing 25 mM Glc for 16 hours. (A) 
Representative IB from three independent experiments and (B, C) results, 
expressed as percent of 25 mM glucose control, representing the mean (± SE, * 
P<0.05) from 3-4 independent experiments. 
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CrPic Induces a Reciprocal Response in SREBP and ABCA1 
 In order to confirm the CrPic-induced change in cellular cholesterol, we 
next studied whether the activity of SREBP-1, a predominantly expressed 
SREBP in 3T3-L1 adipocytes that can stimulate all SREBP-responsive genes 
including those involved in cholesterol homeostasis, was affected in cells treated 
with CrPic. In contrast to our initial thoughts that CrPic may decrease plasma 
membrane cholesterol by repressing the cleavage of the ER/Golgi-localized 125 
kDa precursor SREBP-1, CrPic exposure was associated with a clear loss of this 
precursor from the intracellular membrane fraction (Fig. 10A). At the same time, 
immunoblot analyses of nuclear extracts revealed an increased abundance of the 
68 kDa mature SREBP-1 (Fig. 10B). In parallel, we tested if the increased 
nuclear localization of SREBP-1 induced the predicted shutdown of expression of 
ABCA1, a major player in mediating the cellular efflux of cholesterol. As shown in 
Fig. 10C, plasma membrane fractions prepared from cells treated with CrPic 
displayed a decrease in the basal-state plasma membrane level of ABCA1. 
 Interestingly, the work presented in this section demonstrated a novel 
membrane-based mechanism for the effects of a commonly used supplement, 
chromium, on the regulation of the glucose transport system in 3T3-L1 
adipocytes. To our knowledge, this was the first time that a mechanism had been 
proposed regarding chromium’s beneficial effects on the glucose transport 
system that did not involve direct enhancement of the insulin signaling pathway. 
The work presented in this section further supported a model of membrane-
associated changes that affected glucose transport in adipocytes. This stimulated 
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work dissecting cellular and molecular alterations PM changes that then 
influences GLUT4 translocation and glucose transport.  
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Fig. 10 SREBP-1 and ABCA1 protein response in cells exposed to CrPic. 
PM, intracellular membrane (IM) and nuclear extracts (NE) were prepared as 
described in Material and methods from 3T3-L1 adipocytes treated with 10 nM 
CrPic in serum-free DMEM containing 25 mM Glc for 16 hours. Shown are 
representative IBs for (A) SREBP-1 in the IM fraction, (B) SREBP-1 in the NE 
fraction and (C) ABCA1 in the PM fraction. 
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II. C 
Hexosamine Biosynthesis Pathway Flux Contributes to Insulin Resistance 
via Altering Membrane PIP2 and Cortical F-Actin 
 
1. Summary 
 
 We recently found that plasma membrane (PM) phosphatidylinositol 4,5 
bisphosphate (PIP2)-regulated filamentous actin (F-actin) polymerization was 
diminished in hyperinsulinemic cell culture models of insulin resistance. Here we 
delineated if increased glucose flux through the hexosamine biosynthesis 
pathway (HBP) causes the PIP2/F-actin dysregulation and insulin resistance 
induced by hyperinsulinemia. Increased HBP activity was detected in 3T3-L1 
adipocytes cultured under conditions closely resembling physiologic 
hyperinsulinemia (5 nM Ins for 12 h) and in cells where HBP activity was 
amiplified by 2 mM glucosamine (GlcN), an experimental substance entering the 
HBP distal to the rate-limiting enzyme (GFAT, glutamine:fructose-6-phosphate 
amidotransferase). Both the 5 nM Ins and experimental GlcN challenge induced 
comparable losses of PIP2 and F-actin. In addition to protecting against the 
insulin-induced membrane/cytoskeletal abnormality and insulin-resistant state, 
exogenous PIP2 corrected the GlcN-induced insult on these parameters. 
Moreover, in accordance with HBP flux directly weakening PIP2/F-actin 
structrure, inhibition of GFAT restored PIP2-regulated F-actin structure and 
insulin responsiveness. Conversely, overexpression of GFAT was associated 
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with a loss of detectable PM PIP2 and insulin sensitivity. A slight decrease in 
intracellular ATP resulted from amplifying HBP by hyperinsulinemia and GlcN. 
However, experimental maintenance of the intracellular ATP pool under both 
conditions with inosine did not reverse the PIP2/F-actin-based insulin resistant 
state. Furthermore, less invasive challenges with increased glucose 
concentrations in the absence of insulin, also led to PIP2/F-actin dysregulation. 
Accordingly, we suggest that the functionality of cell systems dependent on PIP2 
and/or F-actin status, such as the glucose transport system, can be critically 
compromised by excessive HBP activity.  
 
2. Results 
 
Hyperinsulinemia- and Glucosamine-Induced Defects in Glucose Transport 
 Previous study by our laboratory has examined insulin- and GlcN-induced 
insulin resistance. The former studies revealed novel PIP2/F-actin defects 
contributing to the insulin-induced insulin resistance. In addition, the later GlcN 
studies showed cell surface O-linked glycosylation in the insulin-resistant cells. 
As a start to probing whether the insulin-induced PIP2/F-actin loss was coupled 
to inappropriate HBP activity, we visualized O-linked glycosylation to ensure 
replication of earlier GlcN findings. Consistent with other reports, strong nuclear 
membrane labeling resulting from nuclear pore complex protein O-linked 
glycosylation was detected in all cells. Concomitant with this strong nuclear 
signal, 3T3-L1 adipocytes exposed to 2 mM GlcN for 12 h displayed a marked  
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increase in cell surface membrane immunoreactivity to an O-GlcNAc-specific 
antibody. A qualitatively detectable increase in PM localized O-linked 
glycosylation was also present in cells treated with 5 nM insulin for 12 h (Fig. 
11A). Inhibition of GFAT with DON reduced the cell surface O-GlcNAc signal 
visualized in the cells exposed to the 12 h insulin treatment, lending support to 
the involvement of the HBP in the insulin-induced increase in O-linked 
glycosylation. Fig. 11B shows the quantitative results of digitally analyzing the O-
GlcNAc signal in multiple boxed regions of the cell surface area in several 
images collected for each group from three to five independent experiments.  
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Fig. 11 Insulin and GlcN induce similar changes in cellular O-linked 
glycosylation. Following 36 h of incubation in DMEM containing 5.5 mM 
glucose, cells were left untreated (Control) or treated overnight (12 h) with 5 nM 
insulin in the presence (12h Ins, +DON) or absence (12h Ins) of DON. A subset 
of cells was treated with 2 mM glucosamine in the absence of insulin (12h GlcN) 
for 12 h. Representative images of cells subjected to immunofluorescence 
microscopy with RL2 antibody (A) and quantitation (B) are shown. (*, P < 0.05 
vs. Control; bar 1). 
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 Consistent with the negative effect of increased HBP activity on insulin-
regulated GLUT4 translocation observed in these models, this acute insulin-
regulated process was impaired for the 12 h Ins- and 12 h GlcN-treated cells, 
respectively (Fig. 12A). Quantitation of these data entailed normalizing the 
GLUT4 signal to wheat-germ agglutinin (WGA)-labeling of the same PM sheets 
(Fig. 12B). These analyses revealed that the chronic insulin and GlcN treatments 
decreased the ability of an acute insulin challenge to stimulate GLUT4 
translocation by 21% and 24%, respectively. DON treatment completely restored 
both insulin-regulated GLUT4 translocation to control levels. Basal and acute 
insulin-stimulated GLUT4 translocations in control cells were not affected by 
DON.  
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Fig. 12 Acute insulin responsiveness is impaired similarly by 
hyperinsulinemia and GlcN. Cells were treated exactly as described in Fig. 1. 
Following treatments, cells were washed, either left untreated (Basal) or acutely 
(30 min) challenged with 100 nM insulin (30' Ins), and GLUT4 translocation and 
glucose transport were determined. Representative images of PM sheets 
subjected to immunofluorescence microscopy with GLUT4 antibody (A, Panels 
1-4 and 9-12) and WGA (A, Panels 2-8 and 13-16), and signal quantitation 
(means ±S.E.) from three to five experiments (B) are shown. All microscopic and 
camera settings were identical between groups. (*, P < 0.05 vs. Control; #, P < 
0.05 vs. Control 30’ Ins).  
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Plasma Membrane and Cytoskeletal Defects 
We recently documented that this failed insulin response induced by the 
12 h Ins treatment reflected a defect in PIP2-regulated cortical F-actin. To test if 
the PIP2/F-actin disturbance resulted from increased glucose flux through HBP, 
we first examined if inhibition of GFAT with DON protected against the insulin-
induced decrease in detectable PM PIP2 and F-actin. For these studies, we used 
a commercially available PIP2 antibody (Assay Designs Inc, Ann Arbor, 
Michigan) that we have previously documented to be specific for PI(4,5)P2. PM 
sheets prepared from 12 h Ins cells displayed a loss in detectable PM PIP2 
compared to control cells (Fig. 13, compare panels 1 and 2). In contrast, DON 
pretreatment completely prevented this decrease (Fig. 13, panel 3). As 
visualized in panels 4 and 5, DON treatment did not appear to affect the control 
level of PM PIP2, but the overnight GlcN treatment was associated with a clear 
reduction in detectable PM PIP2, similar to that induced by the chronic insulin 
conditions. Shown are representative images captured from 8-10 separate 
experiments and again, to ensure that this qualitative measure was performed in 
an unbiased manner, fields of sheets were selected based solely on their staining 
with rhodamine-conjugated WGA (Fig. 13, panels 6-10).  
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Fig. 13 Hyperinsulinemic- and GlcN-states induce a loss in PM PIP2 
detection and cortical F-actin. Representative immunofluorescent images of 
PIP2 (Panels 1-5) and WGA (Panels 6-10) detected in PM sheets treated as 
described in preceding Figs., are shown. Phalloidin stained F-actin and 
propidium iodide labeled nuclei in these cells (Panels 11-16) are shown. Images 
are representative from three to five independent experiments. 
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 In addition to these qualitative measure of signal intensity from 60x 
magnification fields, we also performed three separate population-based assays 
where the PM PIP2 immunofluorescent signal was quantitated on an entire 35-
mm cell culture plate well using the LI-COR Odyssey imaging system as we have 
previously described. As shown in Fig. 4A, PM PIP2 detection in the entire 35-mm 
well area was reduced by 25% by both the chronic insulin exposure and the GlcN 
treatment and DON treatment prevented the insulin-induced PIP2 loss.  
 
Concomitant changes in the cortical F-actin immunofluorescent intensity 
were also detected by confocal imaging (Fig. 13, panels 11-15). In particular, 
microscopic analyses qualitatively revealed that cells treated overnight with 5 nM 
insulin or 2 mM GlcN displayed a reduction in F-actin (Fig. 13, panels 12 and 
15). Also, in the presence of DON, this insulin-induced visualized loss of F-actin 
appeared to be reversed. To ensure the imaging of a comparable number of cells 
we co-stained nuclei with propidium iodine. As performed for the PIP2 analyses, 
we also conducted three separate population-based assays where the F-actin 
immunofluorescent signal was quantitated on an entire 35-mm well area and 
normalized to nuclei. As shown in Fig. 14B, F-actin/nuclei detection was reduced 
by 15-25% by both overnight incubations (bars 1 and 4) and DON treatment 
prevented the insulin-induced F-actin loss (bar 2). 
  
 76 
Fig. 14 Population-based LI-COR Odyssey analyses quantitate a loss in PM 
PIP2 detection and cortical F-actin. For these analyses, PM sheets or cells on 
an entire 35-mm cell culture well were labeled as in Fig. 3 and the fluorescent 
signals in the entire well were quantitated using the LI-COR Odyssey system as 
described in Methods. PM PIP2 (A) and F-actin (B) means ±S.E. from three 
independent experiments are shown. (*, P < 0.05 vs. Control; #, P < 0.05 vs. 12 h 
Ins). 
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Both these microscopic field (Fig. 13) and separate 35-mm entire cell-well 
population-based (Fig. 14) analyses suggest the analogous changes in O-linked 
glycosylation (Fig. 11) and impairments in GLUT4 translocation/2-DG uptake 
(Fig. 12) induced by either 5 nM insulin or 2 mM GlcN result from a similar 
unappreciated HBP-coupled PIP2/F-actin mechanism. Nevertheless work of 
Hresko et al. [147] underscores the importance of measuring intracellular ATP, 
because the use of GlcN can, under certain conditions, result in intracellular ATP 
depletion greater than that induced by insulin, and likely result in non-specific 
defects. 
 
Consistent with our deliberate choice of a low concentration of GlcN with 
the omission of insulin in the medium, we found the loss of intracellular ATP in 
the GlcN treated cells (14.0±5.6%; p=0.042) to be similar to that induced by 5 nM 
insulin (10.4±3.4%; p=0.019) (Fig. 15, bars 1 and 2). Interestingly, although 
inosine prevented this loss of intracellular ATP (Fig. 15A, bars 3 and 4), it did not 
reverse the changes in O-linked glycosylation (data not shown), acute, insulin-
stimulated PM GLUT4 (Fig. 15B)/WGA PM stain (data not shown), PIP2/PM stain 
(data not shown), and F-actin/nuclei (data not shown) induced by these models. 
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Fig. 15 Insulin and GlcN slightly deplete intracellular ATP to similar extents. 
Following 36 h of incubation in DMEM containing 5.5 mM glucose, cells were left 
untreated (Control) or treated overnight (12 h) with 5 nM insulin or 2 mM 
glucosamine in the presence or absence of inosine. The percent changes of 
intracellular ATP from control from three to eight separate experiments are 
shown (A). Values are means ± S.E. (*, P < 0.05). Representative images of PM 
sheet GLUT4 immunofluorescence from insulin-stimulated, insulin-resistant cells 
from three separate experiments are shown (B). 
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Exogenous PIP2 Protects Against GlcN-Induced Loss of Cortical F-Actin 
and Insulin Action 
 It is of interest that experimental replenishment of PIP2, as we previously 
reported [1, 41] or inhibition of GFAT with DON as we report here protects 
against insulin-induced insulin resistance. We reasoned that protection against 
GlcN-induced insulin resistance by PIP2 replenishment would lend credence to a 
coupling between increased HBP activity and PIP2/F-actin dysfunction. As we 
have established in several other studies [1, 41, 142, 148] histone-mediated 
delivery of 1.25 µM exogenous PIP2 into cells displaying a 20-30% loss of 
immunodetectable PIP2 effectively restores this lipid’s PM content to that 
witnessed in control cells (Figs. 16A and 16B).   
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Fig. 16 PIP2 addback restores GlcN-induced PIP2 decrease. During the final 
60 min of control or GlcN incubation, the medium was replaced with the same 
medium enriched with either histone H1 (A, Panels 1, 2, 4, and 5) or 
PIP2/histone H1 (A, Panels 3 and 6). Representative immunofluorescent images 
of PM PIP2 (A, Panels 1-3) and WGA-stained PM (A, Panels 4-6), and 
quantitation of PM PIP2 (B) are shown. Images and means ± S.E. are from three 
to four independent experiments (*, P < 0.05 vs. Control). 
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 This tactic concomitantly restored cortical F-actin structure (Fig. 17A) and 
insulin-stimulated GLUT4 translocation (Figs. 17B and 17C) in GlcN-induced 
insulin-resistant 3T3-L1 adipocytes [Note, WGA-labeling was performed but 
images are not shown. As performed above, the GLUT4 signal was normalized 
to the WGA PM stain, Fig. 17C]. To the best of our knowledge, this is the first 
time the negative effect of GlcN on insulin sensitivity has been experimentally 
eliminated.  
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Fig. 17 PIP2 replenishment protects against GlcN-induced F-actin loss and 
insulin resistance. Control and GlcN cells were treated with either histone H1 or 
PIP2/histone H1 as described in Fig. 16. Phalloidin stained F-actin and propidium 
iodide stained nuclei in these cells (A), insulin-stimulated PM GLUT4 images (B) 
and GLUT4 quantitation (C) are shown. All microscope and camera settings were 
identical between groups and representative images from three independent 
experiments are shown. Values are means ± S.E. from three to five independent 
experiments (*, P < 0.05 vs. Control; #, P < 0.008 vs. 30’ Ins). 
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In line with these DON and GlcN data, GLUT4-eGFP expressing 3T3-L1 
adipocytes co-overexpressing GFAT displayed a loss of plasma membrane PIP2 
compared to non-expressing neighboring cells (Fig. 18, panel 2). Co-expression 
of control empty vector had no effect on plasma membrane PIP2 (Fig. 18, panel 
1). Also, detected in these basal cells is the perinuclear localization of the eGFP-
tagged transporter (Fig. 18, panels 1 and 2). Insulin-stimulated GLUT4-eGFP 
translocation to the plasma membrane was evident in empty vector expressing 
cells (Fig. 18, panel 3), but not in cells overexpressing GFAT (Fig. 18, panel 4). 
As we previously reported [142], acute insulin stimulation in control cells was 
associated with a slight, yet noticeable loss of PM PIP2, reflecting the PI3K-
induced conversion of that lipid substrate to phosphatidylinositol 3,4,5-
trisphosphate (PIP3).  
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Fig. 18 Overexpression of GFAT reduces detectable cell-surface PIP2 
concomitant with a reduction in insulin-stimulated GLUT4–eGFP 
translocation. Differentiated 3T3-L1 adipocytes were electroporated with 50 µg 
GLUT4-eGFP cDNA and 200 µg GFAT cDNA empty vector or GFAT cDNA. The 
cells were allowed to recover for 16 h. Cells were subsequently incubated in 
serum-free medium for 2 h and then left untreated (Basal, Panels 1 and 2) or 
treated (30’ Ins., Panels 3 and 4) with 100 nM insulin for 30 min. Cells were fixed, 
labeled for PIP2, and subjected to confocal fluorescence microscopy. 
Representative images from 3 independent experiments are shown. 
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Glucose Challenge in the Absence of Insulin Negatively Impacts PM PIP2/F-
Actin Structure 
 
 Adipocyte studies presented up to this point utilized the conventional 3T3-
L1 adipocyte differentiation protocol. This protocol calls for 25 mM glucose to be 
present at all stages of differentiation and culturing. As described in the Materials 
and Methods section, our 12 h Ins treatment took place during the last 12 h of a 
48 h low glucose (5.5 mM) incubation. Work by Lin et al. [149] demonstrated that 
it is possible to propagate and differentiate 3T3-L1 cells at 5.5 mM glucose. An 
advantage to be understood further is that these “euglycemic” cultured cells are 
more insulin responsive. In accord, we observed that these cells displayed a 
robust labeling of PM PIP2 that was decreased with exposure to 25 mM glucose 
medium for 16 h alone (Fig. 19A, compare panels 1 and 2). The same was true 
for cortical F-actin (Fig. 19B, compare panels 1 and 2). Also, we found that the 
25 mM glucose challenge alone decreased insulin-regulated GLUT4 
translocation (Fig. 19C, compare panels 1 and 2). A striking observation was the 
complete lack of cytoplasmic and PM O-GlcNAc immunofluoresence in the cells 
propagated, differentiated, and kept in 5.5 mM glucose (Fig. 19D, panel 1); 
whereas, cells cultured under the standard protocol (see Fig. 11, panel 1) or 
under euglycemic conditions and then exposed to 25 mM glucose overnight (Fig. 
19D, panel 2) revealed comparable O-GlcNAc labeling. The effect of high 
glucose on PIP2, F-actin, GLUT4, and O-GlcNAc were all inhibited by DON (Figs. 
19A-D, panel 3), supporting the negative contribution of flux through the HBP. 
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These data were normalized to WGA PM stain (PM PIP2 and GLUT4) or area (F-
actin and O-GlcNAc) and quantitated (Fig. 19E).   
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Fig. 19 High glucose alone induces PIP2/F-actin loss and insulin resistance 
in 3T3-L1 adipocytes that were cultured and differentiated in 5.5 mM 
glucose. Murine 3T3-L1 preadipocytes cultured and differentiated in DMEM 
containing 5.5 mM glucose were left untreated (5.5mM Glu, Panel 1) or treated 
overnight (16 h) with 25 mM glucose (25 mM Glu, Panels 2 and 3) in the absence 
or presence of DON (Panel 3). PM PIP2 (A), F-actin (B), insulin-stimulated PM 
GLUT4 (C), and O-linked glycosylation (D) were determined and quantitated (E) 
as described in preceding Figs. All microscope and camera settings were 
identical between groups and representative images from three independent 
experiments are shown. Values are means ± S.E. from three independent 
experiments (*, P < 0.05 vs. Control).  
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Chapter III 
Perspectives 
 
 
 Mechanism(s) of Cholesterol-Based PM Architectural Changes in Insulin-
 Regulated GLUT4 Translocation  
 
 
 
The studies presented in Chapter II exhibit the importance of membrane 
dynamics on glucose transport in both fat and skeletal muscle. Importantly, the 
previous studies highlight the essentiality of optimal PM cholesterol regulation on 
the cortical F-actin structure required for GLUT4 translocation. Perturbations in 
PM cholesterol amount, such as seen in states of hyperinsulinemia, disrupt 
insulin responsiveness without disturbing the propagation of intrinsic insulin 
signaling properties. Rather, we have observed that diabetogenic insults such as 
hyperinsulinemia and hyperlipidemia [150] redirect the utilization of intracellular 
glucose to the HBP. The notion of glucose toxicity as a mediator of insulin 
resistance stemmed from the studies designed to test the effects of CrPic on 
glucose transport. Interestingly, the evidence gleaned from that study 
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demonstrated that CrPic action was dependent on PM cholesterol accrual 
induced by conditions of excess glucose (hyperglycemia). This led to a set of 
studies which was presented in Chapter IIC distinctively placing the HBP as a 
mediator of insulin resistance in both adipocytes and skeletal muscle myotubes. 
A new joint project undertaken by Kirk Habegger, a recent graduate student in 
the laboratory, and myself focused on testing whether a mechanism existed in 
the development of membrane defects by HBP activation by either 
hyperinsulinemia or hyperlipidemia, particularly PM cholesterol accrual and F-
actin loss. Preliminary data presented here place the HBP as a mediator of PM 
cholesterol accrual through transcriptional changes in cholesterogenic enzymes. 
In direct support of HBP activity and PM lipid coupling, PM prepared from treated 
3T3-L1 adipocytes or L6 myotubes displayed an HBP-dependent increase in 
cholesterol content and impaired GLUT4 function (Fig. 20).  
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Fig. 20 Excess glucose flux results in PM cholesterol accrual. Plasma 
membrane fractions from hyperglycemia-, hyperinsulinemia-, and glucosamine-
treated adipocytes as well as hyperinsulinemia- treated L6-GLUT4myc 
myotubes, exhibit increased cholesterol content. Values are means ± SE of 
membrane cholesterol. (*, P < 0.05 vs. Control). 
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Furthermore, skeletal muscle removed from streptozotocin (STZ)-induced 
hyperglycemic C57Bl/6J mice showed an increase in PM cholesterol content 
(Fig. 21A). In both the cell culture and whole animal models, an HBP- and 
cholesterol-dependent loss of F-actin was evident (Fig. 21B).  
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Fig. 21 Streptozotocin-induced hyperglycemic mice display increased 
membrane-associated defects. Skeletal muscle from STZ-treated mice 
demonstrated (A) increased PM cholesterol and (B) cortical F-actin loss. 
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As shown in Fig. 22, cells displaying HBP-induced PM cholesterol accrual, loss 
of actin filaments, and insulin resistance also demonstrated increased nuclear 
abundance of specificity protein, Sp1; sterol regulatory element binding protein 
(SREBP)-1; and NFY, transcription factors that regulate genes involved in 
cholesterol synthesis. Consistent with O-linked glycosylation of Sp1 participating 
in the maximal transcriptional activation of SREBP-1, this HBP-induced 
modification of Sp1 and upregulation of SREBP-1 gene products and rate-limiting 
enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl CoA reductase 
(Hmgr) was detected (Fig. 22C). These findings seem to causally link increased 
HBP activity to PM cholesterol accrual and cortical F-actin loss that compromises 
the efficient regulation of GLUT4 by insulin. 
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Fig. 22 Nuclear extracts from hyperinsulinemia- and hyperglycemia-treated 
adipocytes demonstrate a cholesterogenic response. (A) Nuclear fractions 
reveal an increase in Sp1, SREBP-1, and NFY in 3T3-L1 adipocytes cultured in 
hyperinsulinemic conditions. (B) O-linked glycosylation of Sp1 is elevated in 3T3-
L1 adipocytes cultured in hyperglycemic conditions and this corresponds to an 
increase in HMGR protein. (C) Hyperinsulinemic 3T3-L1 adipocytes display 
elevated Hmgr expression. Values are means ± SE of fold Hmgr expression from 
control. (*, P < 0.05 vs. Control). 
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In order to firmly place the HBP at the crux of accumulating PM cholesterol and 
development of insulin resistance, we utilized the well-characterized L6-
GLUT4myc cell culture system, that has been previously shown to develop 
insulin resistance by hyperinsulinemia [1], to genetically manipulate a component 
of the HBP. Utilizing siRNA technology, we were successfully able to knockdown 
OGT ~95% (Fig. 23, A and B). As shown in Fig. 23C, the knockdown of this 
protein led to a global decrease in O-linked glycosylation of these myotubes. 
Preliminarily, stimulators such as hyperinsulinemia and palmitate were ineffective 
in further increasing RL2 labeling. Further parameters important in GLUT4 
translocation were tested which included PM cholesterol, F-actin structure, and 
Hmgr mRNA expression. Preliminary data with siOGT myotubes demonstrated 
that PM cholesterol accrual was sufficiently prevented in hyperinsulinemic cells 
that were lacking OGT (Fig. 23E). An interesting observation that we noted was 
that siOGT controls exhibited increased PM cholesterol compared to siScramble 
cells. However, more replicates will be needed to confirm this. Concomitant with 
this prevention of accumulation of PM cholesterol due to hyperinsulinemia, 
expression of Hmgr mRNA was unchanged in siOGT myotubes treated with 
hyperinsulinemia compared to its relative control (Fig. 23G). This was in direct 
contrast to hyperinsulinemia-treated siScramble myotubes with increased Hmgr 
expression compared to its relative control. Additionally, the distal F-actin 
disturbances were ablated in siOGT myotubes treated with hyperinsulinemia. 
Hyperlipidemia, which has been shown by many groups including ours [150, 
151], to be a potent stimulator of HBP activity also caused PM cholesterol 
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accrual and defects in cortical F-actin structure necessary for GLUT4 
translocation. Knocking down OGT in these cells also prevented the 
dysregulation of PM cholesterol and cortical F-actin induced by palmitate 
treatments (Fig. 23, D and F). Taken together, these preliminary data offer some 
exciting evidence that these diabetogenic insults mediate insulin resistance 
through disturbances seen at the PM via an HBP-mediated glycosylation events 
that when inhibited protected the cell from developing insulin resistance and 
glucose transport abnormalities. 
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Fig. 23 siRNA-mediated knockdown of O-Glycosyltransferase (OGT) in L6-
GLUT4myc myotubes. (A) Calcium-phosphate based transfection of L6-
GLUT4myc myotubes with siGlo oligos revealed sufficient transfection efficiency. 
(B) siRNA-mediated knockdown of OGT revealed ~95% knockdown efficiency 
with oligo 75. (C) O-linked GlcNAc of palmitate-treated siOGT myotubes. (D & E) 
PM cholesterol in palmitate- and hyperinsulinemia-treated siOGT myotubes. (F) 
F-actin and (G) Hmgr expression in palmitate- and hyperinsulinemia-treated 
siOGT myotubes Values are means ± SE. (*, P < 0.05 vs. Scramble [Scrm] 
Control). 
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Another interesting observation made during the course of these thesis 
studies is that CrPic action on reducing PM cholesterol may be attributed to a 
protein that is important in the energy regulation of a cell, 5’-AMP activated 
protein kinase (AMPK). When active, the responsibility of AMPK is to conserve 
energy for the cell by inhibiting energy-consuming reactions such as fatty 
acid/sterol synthesis via phosphorylation. Previous studies have demonstrated 
that AMPK activation occurs in response to physiologic exercise training [58] and 
the first-line antidiabetic medication, metformin [152]. Yet, its role in adipocytes 
was still controversial and undetermined [91]. As previously mentioned, AMPK is 
able to inhibit cellular cholesterol synthesis by phosphorylation of HMGR. 
Preliminary data presented here exhibit that CrPic activated AMPK as evidenced 
by phosphorylation of AMPK on its Threonine 172 residue (Fig. 24A), which has 
been implicated in the activation of the kinase. Consistent with AMPK activation 
occurring due to CrPic, we found increased phosphorylation on Acetyl-CoA 
carboxylase (ACC), a downstream substrate of AMPK (Fig. 24C). Using an 
antibody specific to a phosphorylation target of HMGR by AMPK, we observed 
that adipocytes, in response to CrPic, displayed increased phosphorylation on 
this serine residue targeted by AMPK. AICAR, an AMP analog that activates 
AMPK by directly interacting with its allosteric site [153], showed a similar 
increase in phosphorylation of HMGR (Fig. 25). 
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Fig. 24 CrPic stimulates phosphorylation and activation of AMPK. (A) CrPic-
treated adipocytes displayed early and sustained phosphorylation of AMPK. (B) 
CrPic had no effect on the level of total AMPK. (C) Treating adipocytes for 16 h 
with CrPic resulted in increased phosphorylation of a downstream target of 
AMPK, Acetyl-CoA Carboxlase. 
A) IB: P-AMPK-α (Thr172)
62 kDa
CrPic (hr)
C) IB: P-ACC (Ser79)
CrPic: +-
0 0.5 1.0 4.0 16.0
B) IB: AMPK-α
62 kDa
0 0.5 1.0 4.0 16.0
280 kDa
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Fig. 25 CrPic induced phosphorylation of HMGR similar to that a known 
AMPK activator, AICAR. (A) Using a phospho-specific antibody to HMGR that 
recognized phosphorylation by AMPK, 16 h CrPic treatment stimulated HMGR 
phosphorylation. (B) AICAR, used as a positive control, caused a similar 
increase in HMGR phosphorylation. Total HMGR was unaffected by CrPic or 
AICAR. 
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Pilot studies examining the mechanism by which CrPic activates AMPK are 
currently being pursued. However, evidence from CrPic-treated 3T3-L1 
adipocytes does not display a loss of ATP compared to that of control adipocytes 
suggesting that CrPic action is not dependent on an increase in the AMP:ATP 
ratio (Fig. 26). Other mechanisms by which CrPic may activate AMPK are being 
investigated. These mechanisms in question include LKB1, a upstream kinase 
known to phosphorylate AMPK on its Thr172 residue; Calcium 
(Ca2+)/Calmodulin-dependent Protein Kinase Kinase 2 (CaMKK2) protein, 
another protein that targets AMPK phosphorylation on its Thr172 residue; and 
decreased activity of Protein Phosphatase 2C (PP2C), a protein that 
dephosphorylates and inactivates AMPK. These three upstream 
activators/deactivators of AMPK regulation may play a key role in CrPic action on 
glucose transport and further explain the benefits of CrPic seen in hyperglycemic 
adipocytes. Taken together, these preliminary data offer a potentially exciting 
new stimulator of AMPK by an inexpensive, readily available supplement. Much 
like the mechanism responsible for exercise-induced benefits on glucose 
transport, activating AMPK via easy lifestyle modifications such as increased 
supplementation with CrPic may prove to be a worthwhile therapy for diabetic 
individuals. 
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Fig. 26 ATP amount unchanged when adipocytes were treated with CrPic. 
3T3-L1 adipocytes treated with 10 nM CrPic (16 h) demonstrated no change in 
ATP levels compared to control (white bar).  
  
ns
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 Although careful longitudinal study is required to test whether these 
membrane/cytoskeletal defects precede documented signaling defects in vivo, 
several cross-sectional studies from other groups demonstrate a clear 
association between excess glucose and membrane/cytoskeletal disorganization. 
For example, isolated neutrophils from patients with type 2 diabetes display 
decreased actin polymerization compared to neutrophils from non-diabetic 
control subjects [154, 155]. This impairment is associated with persistent 
expression of the endothelial adhering β2 integrin CD11b/CD18, potentially 
exacerbating vascular dysfunction in diabetic patients. Also, diabetic retinal 
endothelial cells have a prominent reduction in F-actin integrity, a finding closely 
linked to vascular leakage [156]. Loss of rat mesangial cell F-actin has also been 
reported after exposure to early-diabetic state conditions [157, 158], possibly 
causing diabetic hyperfiltration. Further human support has been derived from 
collected erythrocytes from overweight insulin-resistant individuals showing 
marked changes in the phospholipid composition of the PM [159, 160], some of 
which may directly affect the actin cytoskeleton. Current animal studies are 
underway to test these findings in vivo. In direct support of our findings, we have 
observed that epitrochlearis skeletal muscle from insulin-resistant, 
hyperinsulinemic Zucker fatty rats display a loss of F-actin structure compared to 
that in muscle from lean insulin-sensitive littermates [1]. Together, these human 
and animal observations highlight that F-actin integrity is potentially influenced by 
the glycemic state. 
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In line with the preliminary data identifying glucose flux through the HBP 
as a stimulator of cholesterol accrual, Yang et al. recently observed that OGT 
overexpression increased hepatic cholesterol content [161]. It is important to note 
that those recent studies by Yang et al. show that OGT has a phosphoinositide-
binding domain, and after insulin stimulation PIP3 recruits OGT from the nucleus 
to the PM, where this enzyme catalyzes dynamic modification of the insulin 
signaling pathway by O-GlcNAc [161]. These signaling events target specific 
residues on the IRS-1 and Akt proteins (e.g., phosphorylation of Akt on threonine 
308, but not serine 473, is decreased). Although we have not witnessed changes 
in signaling, we have not specifically monitored phosphorylation of threonine 308. 
In another recent article Dentin et al. report that the transcriptional regulatory 
protein called transducer of regulated cAMP response element-binding protein 2 
(TORC2, also known as CRTC2 [162]) is a target of O-linked glycosylation. The 
modification of CRTC2 activates glucose production in the liver and is an 
example of a mechanism by which glucose serves a signaling function in 
controlling a process, in this case, metabolism in the liver. Studies we are 
currently conducting are addressing the possibility that increased HBP activity 
negatively impacts PIP2/F-actin structure essential for insulin-regulated GLUT4 
translocation and glucose transport via increasing cellular cholesterol synthesis 
and PM cholesterol accrual. 
  
Various nutritional components of the diabetic milieu - including excess 
insulin, glucose, and lipids - all resulted in an accumulation of PM cholesterol in 
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both 3T3-L1 adipocytes and L6 myotubes in this study. New work from our 
laboratory also demonstrated that incubating L6 myotubes with a physiologic 
dose of palmitate resulted in a substantial increase in cellular O-linked 
glycosylation. Further, palmitate-treated myotubes exhibited increased PM 
cholesterol, decreased cortical F-actin, and a loss of insulin responsiveness as 
assessed by GLUT4 translocation and glucose transport [150]. These findings 
are supported by preliminary data generated by Kirk Habegger where L6 
myotubes simply overexpressing GFAT displayed a trend towards an increase in 
O-linked glycosylation (31±17% p=0.21) while demonstrating a reciprocal loss of 
cortical F-actin (48±25% p=0.20) (data not shown). Further evidence for the role 
of HBP in the development of insulin resistance is offered by other groups. Arias 
et al. concluded that increased O-linked glycosylation by inhibiting O-GlcNAcase, 
an enzyme that catalyzes the removal of O-GlcNAc from proteins, induces insulin 
resistance in rat epitrochlearis muscle. Interestingly and consistent with data 
generated from our laboratory, this insulin resistance was independent of insulin 
signaling defects as assessed by normal phosphorylation of Akt, GSK3α, 
GSK3β, and AS160 [77]. Further evidence regarding the importance of HBP on 
the progression of diabetes is present in that the intramuscular content of UDP-
GlcNAc is increased in diabetic mice [163, 164]. McClain et al. have 
demonstrated that increased hexosamine flux in adipocytes from GFAT 
overexpressing mice resulted in skeletal muscle insulin resistance and altered 
regulation of leptin and adiponectin. Additionally, adipocytes overexpressing 
GFAT from these transgenic mice were associated with an increase in total lipid 
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synthesis consistent with data that increased hexosamine flux is associated 
lipogenic processes [165]. Similarly, treating C2C12 myoblasts with glucosamine 
resulted in lipid accumulation due to transcriptional changes and mRNA 
expression levels, including an increase in SREBP-1c [166]. SREBP-1c is 
encoded from the SREBP-1 gene that also encodes an almost identical protein, 
SREBP-1a. Interestingly, preliminary data presented in this section are 
consistent with increased flux through the HBP stimulating lipogenic gene 
expression including an upregulation of Hmgr mRNA in both hyperinsulinemia- 
and palmitate-treated adipocytes and myotubes. SREBP-1 has been shown play 
an active role in transcriptional regulation of FA synthesis and albeit, to a lesser 
extent, regulation of cholesterol synthesis genes [79]. Our data in both 3T3-L1 
adipocytes and L6 myotubes are consistent with a transcriptional increase in 
cholesterogenic genes in the development of insulin resistance.  
 
Although this data is still preliminary, these findings highlight an 
importance of HBP-mediated membrane disturbances in the development of 
insulin resistance that may be reversible and offer exciting new therapies to slow 
the progression/worsening of insulin resistance. Future studies in the laboratory 
are directed at understanding the possible reversibility of this insulin resistance 
through PM cholesterol depletion as well as further understanding the molecular 
role of O-linked glycosylation modifications on gene transcription involved in 
lipogenesis and glucose transport.  
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As has been previously discussed, the beginning of these thesis studies 
had an interest in understanding the development of insulin resistance and 
progression to diabetes, I also was very interested in understanding a therapy 
that could benefit insulin action/glucose metabolism. Interestingly, recent work in 
the laboratory demonstrated the importance of the essential nutrient chromium 
on membrane properties, particularly depleting PM cholesterol, enhancing 
glucose transport in 3T3-L1 adipocytes [57]. In particular, our studies show that 
CrPic recruits intracellular GLUT4 to an area adjacent to the PM. In the presence 
of insulin, these juxtaposed transporters become functional by fusing into the PM 
and enhancing insulin-stimulated glucose transport. Recent clinical data is 
consistent with the theory that Cr3+ supplements, especially CrPic, enhance the 
metabolic action of insulin and lower certain risk factors for cardiovascular 
disease that are influenced by cellular cholesterol homeostasis. For example, 
several randomized, placebo-controlled, double blind clinical tirals, found 
supplementation with CrPic (200-1000 µg Cr/day) decreased total cholestrol 
and/or low density lipoprotein (LDL) cholesterol [167-169]. Interestingly, data 
from our laboratory has shown that the benefits experienced by CrPic treatments 
are dependent on the metabolic status of cells. In particular adipocytes that were 
in the presence of 25 mM glucose only benefited from CrPic whereas adipocytes 
that were in 5.5 mM glucose, a concentration akin to a euglycemic individual, did 
not experience an enhancement in glucose transport. Concomitant with this 
discrepancy in CrPic-mediated events on glucose transport between 
hyperglycemic and euglycemic cells, reduction of PM cholesterol by CrPic 
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occurred in adipocytes incubated in 25 mM glucose conditions only. Taken 
together, these data are consistent with CrPic action on glucose transport being 
dependent on PM cholesterol lowering. Further evidence for the necessary role 
of cholesterol reduction by CrPic in enhancing glucose transport was 
demonstrated by the addback of exogenous cholesterol in CrPic-treated cells 
preventing the beneficial effect of CrPic on both GLUT4 mobilization and insulin-
stimulated glucose transport. An exciting prediction from these findings is that 
Cr3+ supplementation may lower blood glucose by altering the PM composition of 
cholesterol and F-actin, important in GLUT4 translocation, in fat and skeletal 
muscle cells. However, since Cr3+ supplementation has the greatest benefit in 
overweight, insulin-resistant individuals, a presumption also has to be that cells 
from these individuals possess cholesterol-laden plasma membranes. In 
contrast, the PM cholesterol content of cells from non-diabetic subjects with 
normal insulin sensitivity and glucose tolerance would be lower and not be 
affected by Cr3+. Recent evidence from our laboratory is consistent with a 
cholesterol component of glucose intolerance clinically in that human skeletal 
muscle biopsies revealed an inverse correlation between membrane cholesterol 
and whole-body glucose disposal [150]. Taken together, these data demonstrate 
an importance for the role of PM cholesterol lowering in antidiabetic 
interventions, such as CrPic supplementation. 
 
 Studies were also undertaken to dissect a mechanistic basis for the PM 
modifications seen in the enhancement of glucose transport by CrPic. Although 
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the actions of AMPK are still imperfectly understood, the role of this protein in the 
enhancement of both basal and insulin-stimulated glucose transport has been 
well documented. Additionally, the ability of AMPK to inactivate energy 
consuming pathways (i.e. fatty acid and sterol synthesis) has been implicated in 
slowing down diabetes progression. In particular, the role of an activated AMPK 
on inhibiting cholesterol synthesis via phosphorylation of HMGR, the rate-limiting 
enzyme, was an attractive concept. Interestingly, data that we and others have 
now generated has firmly placed AMPK as a mediator of Cr3+-containing 
supplements on glucose transport. Recent evidence from our laboratory has 
shown that direct AMPK activation with 5-aminoimidazole-4-carboxamide-1-beta-
D-ribonucleoside (AICAR) or 2,4-dinitrophenol (DNP) in L6 myotubes [58] can 
acutely and chronically affect basal and insulin-regulated glucose transport, 
similar to that experienced by CrPic. Downstream targets of AMPK, including 
acetyl-CoA carboxylase (ACC) and HMGR, bears significant merit as both can 
affect glucose transport. ACC catalyzes the conversion of acetyl CoA to malonyl 
CoA, an inhibitor of translocation of long chain fatty acyl (LCFA) groups from the 
cytosol to the mitochondrial matrix for fatty acid oxidation. Inactivation of ACC by 
AMPK in insulin-resistant skeletal muscle would be predicted to decrease excess 
FAs and several metabolites including acyl-CoAs, ceramides, and diacylglycerol 
that activate kinases (e.g. PKC, JNK, IKKβ) that are detrimental to insulin action 
via increasing the inhibitory serine phosphorylation of insulin signaling cascade 
[170-172] perhaps providing an explanation to the beneficial effects of Cr3+ on 
insulin signaling. Study by Zhao et al. showed that activation of AMPK by Cr(D-
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Phe)3 in H9c2 myoblasts [173]. This activation of AMPK in this skeletal muscle 
cell line sufficiently stimulated glucose transport. Importantly, when AMPK activity 
was pharmacologically inhibited, the enhanced glucose uptake was blocked. 
Another study performed in 3T3-L1 adipocytes revealed that AMPK activation by 
Cr3+ decreased secretion of resistin, an adipokine associated with impaired 
glucose transport [174]. All these data taken together, the proposed mechanism 
that AMPK activity is being increased by Cr3+ may be a feasible explanation for 
the multiple actions in both relieving glucose and lipid disorders in metabolically 
challenged individuals.  
  
Taken together, the published and preliminary work presented in these 
thesis studies have demonstrated that insulin resistance, as a result of HBP 
activation, impairs PIP2 regulation of F-actin which when corrected protects 
against the insulin resistance. Consistent with these findings, we have also 
observed that the PIP2/F-actin impairment is accompanied by a possible HBP-
mediated increase in PM cholesterol. Correction of this increase in PM 
cholesterol with various cholesterol-lowering strategies, particularly the use of 
chromium, enhances insulin-stimulated glucose transport. In contrast to 
downregulation of insulin signal transduction observed in other studies, we have 
found that proximal insulin signaling is still intact yet these membrane-associated 
parameters account for alterations in insulin action. 
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Chapter IV 
Experimental Procedures 
 
1. Materials 
Murine 3T3-L1 preadipocytes were purchased from American Type 
Culture Collection (Manassas, VA). Dulbecco's modified Eagle's medium 
(DMEM) was from Invitrogen. Fetal bovine serum and bovine calf serum were 
obtained from Hyclone Laboratories Inc. (Logan, UT). Polyclonal rabbit caveolin-
1 and polyclonal goat GLUT4 antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA). Monoclonal mouse phosphatidylinositol 
4,5-bisphosphate antibody and phosphatidylinositol 3,4,5-trisphosphate antibody 
were purchased from Assay Designs Inc. (Ann Arbor, MI). Anti-phospho-AMPK 
(Thr172), anti-phospho-ACC (Ser79), and anti-AMPK was from Cell Signaling 
(Danvers, MA). Anti-HMGR and anti-ACC were from Millipore (Temecula, CA). 
Anti-phospho-HMGR (Ser 879) was from Kinasource (Scotland, UK). Anti-
ABCA1 antibody was from Novus Biologicals (Littleton, CO). Anti-β-actin 
antibody was from Cytoskeleton (Denver, CO). Anti-SREBP-1, anti-SREBP-2, 
anti-NFY, anti-Sp1, anti-Lamin B were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Monoclonal mouse GLUT4 antibody was purchased from 
Biogenesis (Kingston, NH). Near-infrared IR-dye 800- and 700-conjugated anti-
mouse IgG secondary antibodies were purchased from LI-COR Biosciences 
(Lincoln, NE) or Rockland (Gilbertsville, PA). Amplex Red Cholesterol Assay Kit 
was purchased from Molecular Probes (Eugene, OR). Rhodamine red-X/FITC-
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conjugated donkey anti-rabbit or goat anti-mouse antibodies were from Jackson 
Immunoresearch Inc. (West Grove, PA). Fatty acid free BSA was from MP 
Biomedicals (Solon, OH). Unless indicated, all other chemicals and used were 
from Sigma. 
 
2. Cell culture and treatments 
3T3-L1 adipocyte culture and induction of insulin resistance. 
Preadipocytes were cultured and differentiated as described previously [56]. All 
studies were performed on cells which were between 8 and 12 days post- 
differentiation. Insulin resistance was induced by incubating cells with 5 nM 
insulin for 12 h or DMEM containing 10% FBS and 2 mM GlcN for 12 h, in the 
absence of glucose, glutamine, and insulin (hereafter referred to as 12 h GlcN). 
Acute insulin stimulation was achieved by spiking the cells with 100 nM insulin 
during the last 30 min of incubation. βCD was used to remove (2.5 mM βCD) or 
add (1 mM-5 mM βCD loaded with cholesterol) cholesterol as previously 
described [56] for 30 min prior to insulin stimulation. Adipocytes were also 
cultured in DMEM/10% fetal bovine serum growth medium containing either 5.5 
or 25 mM glucose for 48 h before the experimental treatment. Cells were treated 
with serum-free DMEM with or without 10 nM CrPic (Nutrition 21, Purchase, NY) 
for 16 hours. 
L6-GLUT4myc culture and induction of insulin resistance. Rat L6-
GLUT4myc (generously obtained from Dr. Amira Klip, The Hospital for Sick 
Children, Toronto, Canada) were cultured as previously described [1]. Myoblasts 
 113 
were maintained in α-Minimum essential medium (α-MEM) containing 5 mM 
glucose and 10% fetal bovine serum (FBS; HyClone Laboratories, Grand Island, 
NY), and differentiated into multinucleated myotubes with 2% FBS. All studies 
used myotubes between 4 and 6 days post-initiation of differentiation. 
Hyperinsulinemia induction of insulin resistance was performed by treating cells 
with 5 nM insulin for 12 hr in DMEM supplemented with 1%FBS. 
 
3. Plasma membrane sheet assay 
 Preparation of plasma membrane sheets from the adipocytes was 
performed as previously described [56]. After the isolation of plasma membrane 
sheets, these purified membranes were used for immunofluorescence. The 
sheets were fixed for 20 min at 25°C in a solution containing 2% 
paraformaldehyde, 70 mM KCl, 30 mM HEPES, pH 7.5, 5 mM MgCl2 and 3 mM 
EGTA. The sheets were then blocked in 5% milk or Odyssey Blocking Buffer (LI-
COR, Lincoln NE) for 60 min at 25°C and incubated overnight at 4°C with a 
1:1000 dilution of monoclonal GLUT4 antibody, followed by incubation with a 
1:100 dilution of IR-dye-800-conjugated anti-mouse IgG secondary antibody for 
60 min at 25°C. The amount of glucose transporter on the plasma membrane 
was quantitated by digital image processing as described previously [142, 175]. 
 
4. Subcellular fractionation  
 3T3-L1 Adipocyte Fractionation. Adipocyte subcellular fractions were 
obtained using the differential centrifugation method previously described [176] 
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with slight modification. Briefly, control and experimentally-treated 3T3-L1 
adipocytes were washed and resuspended in HES buffer (20 mM HEPES, pH 
7.4, 1 mM EDTA and 255 mM sucrose containing 1 mM PMSF, 10 µg/ml 
pepstatin, 10 µg/ml aprotinin, and 5 µg/ml leupeptin). Cell lysates were prepared 
by shearing the cells through a 22-gauge needle 10 times. Lysates were then 
centrifuged at 19,000 x g for 20 min at 4°C. The intracellular membrane pellet 
was obtained by centrifugation of the resulting supernatant at 180,000 x g for 75 
min at 4°C. The plasma membrane pellet was obtained by resuspending the 
pellet from the initial 19,000 x g centrifugation in HES buffer followed by layering 
onto a 1.12 M sucrose cushion for centrifugation at 100,000 x g for 60 min. The 
plasma membrane layer was removed from the sucrose cushion and centrifuged 
at 40,000 x g for 20 min. All pelleted fractions were resuspended in a detergent-
containing lysis buffer and assayed for soluble protein content.  
 L6-GLUT4myc Fractionation. Crude plasma membrane fractions were 
obtained using a differential centrifugation method as detailed by Khayat et al. 
[177], with slight modifications. Briefly, skeletal muscle or L6-GLUT4myc 
myotubes were washed, resuspended in HES buffer (20 mM HEPES, pH 7.4, 1 
mM EDTA, and 255 mM sucrose containing 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 µg/ml pepstatin, 10 µg/ml aprotinin, and 5 µg/ml leupeptin), and 
processed by polytron homogenization (15 s) or shearing the sample through a 
22-gauge needle 10 times, respectively. Lysates were then centrifuged at 5,000 
×g for 20 min at 4°C. The supernatant was subjected to centrifugation at 100,000 
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×g for 30 min. The pellet was resuspended in HES buffer and assayed for protein 
(Bradford) and cholesterol (Amplex Red) content as previously described [178] 
 
5. Glucose transport assay 
3T3-L1 adipocytes were either untreated or stimulated with 100 nM insulin 
for 30 min and exposed to 50 µM 2-deoxyglucose containing 0.5 µCi of 2-[3H] 
deoxyglucose in the absence or presence of 20 µM cytochalasin B. Glucose 
transport was determined as previously described [41].  
 
6. Preparation of cell lysates and immunoblotting 
Cell lysates were prepared from 100-mm plates of 3T3-L1 adipocytes 
following the appropriate treatments. Cells from each plate were washed two 
times with ice-cold PBS and scraped into 1 ml of lysis buffer (25 mM Tris, pH 7.4, 
50 mM NaF, 10 mM Na3PO2O7, 137 mM NaCl, 10% glycerol, and 1% Nonidet P-
40) containing 2 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4, 5 µg/ml 
aprotinin, 10 µM leupeptin, and 1 µM pepstatin A, then rotated for 15 min at 4°C. 
Insoluble material was separated from the soluble extract by microcentrifugation 
for 15 min at 4°C. To assess whole cell GLUT4 content, crude cellular membrane 
was prepared as previously described [57]. To ensure equal loading, protein 
concentrations were determined by the Bradford method and equivalent protein 
amounts of each sample were loaded onto an acrylamide gel. Samples were 
subjected directly to SDS-PAGE, as described below. 
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7. Preparation of nuclear extracts 
 Nuclear extracts were collected as previously described [179]. Briefly, 
3T3-L1 adipocytes were washed with PBS and 2 ml of hypotonic buffer (10 mM 
HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT containing 20 mM 
leupeptin, 2 mM pepstatin, 2 mM aprotinin and 0.5 M PMSF). Cell lysates were 
prepared by shearing the cells through a 22-gauge needle 5 times. Prepared 
lysates were centrifuged at 800 g for 10 min at 4°C. The pellet was then carefully 
dried and resuspended in 0.5 ml of buffer C (10 mM HEPES, pH 7.4, 0.42 M 
NaCl, 25% glycerol (v/v), 1.5 mM MgCl2, 0.5 mM EDTA containing 20 mM 
leupeptin, 2 mM pepstatin, 2 mM aprotinin and 0.5 M PMSF). Nuclei were then 
visualized by staining with 0.2% trypan blue. Proteins were allowed to swell out 
of the nuclei by vortexing for 15 s every 10 min for 40 min. The mixture was then 
centrifuged at full speed in a microcentrifuge at 4°C for 15 min. Supernatant was 
collected and assayed for soluble protein content. 
 
8. Electrophoresis and immunoblot analysis 
Cell lysate fractions were separated by 10% SDS-PAGE (GLUT4) or 7.5% 
SDS-PAGE and the resolved fractions were transferred to nitrocellulose 
membrane (Bio-Rad, Hercules, CA). Proteins were immunoblotted with either a 
phospho-specific Akt, p-AMPK, p-ACC, SREBP-1, NFY, Sp1, RL-2, or β-actin 
antibody. Equal protein loading was confirmed by Ponceau staining and by 
immunoblot analysis for β-actin, Caveolin-1, or Lamin B for nuclear extracts. All 
immunoblots were analyzed via LI-COR quantification. 
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9. PM & Actin Analyses 
Plasma membrane sheets were prepared as previously described [41, 
142]. Briefly, following treatments, cells were fixed by incubation for 20 min in a 
2% paraformaldehyde solution containing PBS (GLUT4 analyses) or TBS (PIP2 
analyses), and these membranes were used for immunofluorescence. For 
GLUT4 immunofluorescence, incubation with a 1:1000 dilution of GLUT4 
antibody was followed by incubation with a 1:50 dilution of FITC-conjugated 
secondary antibody, both for 60 min at 25°C. For PIP2 immunofluorescence, 
incubation with a 1:50 dilution of PIP2 antibody was performed for 30 min at 
37°C. Appropriate FITC-conjugated secondary antibody was added for 60 min at 
25°C. For labeling of actin after fixation, cells were incubated with 5 mg/ml of 
FITC-conjugated phalloidin for 2 h at 25°C (Confocal analyses) or blocked in fish 
serum (1 h at 25°C) and labeled with a 1:100 dilution of F-actin specific primary 
antibody (overnight at 4°C; LI-COR analyses). All PM sheet and cell images were 
obtained using the Zeiss LSM 510 NLO Confocal Microscope, and all microscope 
settings were identical between groups. Images were quantitated with the LI-
COR infrared imaging system as previously described [1, 142, 180]. 
 
10. Immunofluoresence Quantitation 
For GLUT4 quantitation, plasma membrane sheets were prepared and 
labeled as described above. The amount of glucose transporter on the plasma 
membrane was quantitated by digital image processing as described previously 
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[57, 142, 175]. To ensure that quantitation was performed in an unbiased 
manner, fields of sheets were selected based solely on their staining with 
rhodamine-conjugated wheat-germ agglutinin (WGA). Additional population-
based quantitation of PIP2 and F-actin was done using the Odyssey infrared 
imaging system (LI-COR, Lincoln, NE) as previously described [1, 142, 180]. 
 
11. RNA isolation and measurement using RT-PCR  
 L6-GLUT4myc myotubes and 3T3-L1 adipocytes were treated with or 
without 5 nM insulin for 12 hours, washed twice in ice cold PBS. Cells were lysed 
using a Qiagen QIAshredder and RNA was isolated using a Qiagen RNeasy mini 
kit. RNA was reversed transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) for production of a RT-PCR template. 
Reactions were performed in a 96-well plate format using the ABI Prism 7000 
Sequence Detection System (Applied Biosystems). Each reaction contained the 
following: 12.5 µL of SYBR GREEN (Applied Biosystems), 500 nM of each 
primer, cDNA, and RNase free water up to a total volume of 25 µL. The ΔΔCt 
method of relative quantification using real-time quantitative PCR was used. Data 
are expressed as the ratio of Hmgr to 36B4 for 3T3-L1 adipocytes using primers 
specific for the mouse Hmgr gene (forward 5’-TGT GGG AAC GGT GAC ACT 
TA-3’; reverse 5’-CTT CAA ATT TTG GGC ACT CA-3’) and mouse 36B4 gene 
(forward 5’-AAG CGC GTC CTG GCA TTG TCT-3’; reverse 5’-CCG CAG GGG 
CAG CAG TGG T-3’) with an annealing temperature of 60°C. Data are 
expressed as the ratio of Hmgr to Gapdh for L6 myotubes using primers specific 
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for the rat Hmgr gene (forward 5’-TGT GGG AAC GGT GAC ACT TA-3’; reverse 
5’-CTT CAA ATT TTG GGC ACT CA-3’) and rat Gapdh gene (forward 5’-ATG 
GCC AGC CTC GTC CCG TAG ACC AAA ATG-3’; reverse 5’-AAG TGG GCC 
CCG GCC TTC TCC AT-3’) with an annealing temperature of 60°C. 
 
12. ATP measurement. 
 Intracellular ATP content was measured using a luminescence ATP 
detection assay system (ATPliteTM, PerkinElmer Inc.) as we have previously 
described [181]. Briefly, following experimental treatments, 3T3-L1 adipocytes 
were lysed using a mammalian cell lysis buffer which inactivates endogenous 
ATPase. Subsequently whole cell lysate was incubated with substrate buffer and 
luminescence was detected using the SpectraMax M2 (Molecular Devices). 
Luminescence was converted to actual ATP content (nM) by use of an ATP 
standard curve. ATP concentrations were normalized for protein concentration 
determined by the Bradford method. 
 
13. siRNA design and transfection. 
 Three independent oligonuceotide sequences, designed and purchased 
from Ambion (Austin, TX), were tested for OGT. The oligonucleotides with the 
highest knockdown efficiency for OGT was CAU UUA UGA CAA UCG AAU Att 
(siRNA ID#: s130675). Only one oligo was necessary for OGT knockdown 
studies. Ambion’s Negative Control #1 siRNA (Cat #:4635) was used as a control 
in all experiments. For all knockdown experiments cells were seeded as 
 120 
described before. Cells were first transfected at approximately 48 hr post seeding 
(or ~60% confluency). Calcium phosphate transfection protocol was utilized as 
follows, 60 pmol of siRNA was added to siRNA mix: 15 µl ddH2O, 15 µl Buffer A 
(0.5 M CaCl2, 0.1 M HEPES (pH 7.0)), and 30 µl Buffer B (0.28 M NaCl, 0.75 mM 
NaH2PO4, 0.75 mM Na2HPO4, 0.05 M HEPES (pH 7.0)) and after 10 min at room 
temperature, the siRNA mix was added to each well of a 12 well plate containing 
600 µl DMEM + 5% FBS and incubated 12-16 hr. Following 12-16 hr incubation, 
media was aspirated and replaced with DMEM+2% FBS. Additional transfection 
was repeated 72 hr after initial transfection. Cells were treated and assayed 72 hr 
after final transfection. 
 
14. Statistics  
 Values are presented as means ±SE. The significance of differences 
between means was evaluated by analysis of variance. Where differences 
among groups were indicated, the Neumann-Keuls test was used for post hoc 
comparison between groups. GraphPad Prism 4 software was used for all 
analyses. P < 0.05 was considered significant. 
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